Harvard Bioscience (HBIO) 10-Q 8 Aug 19 2019 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2019	Aug. 01, 2019
Document And Entity Information [Abstract]
Document Type	10-Q
Document period end date	Jun. 30, 2019
Amendment flag	false
Document Period Focus	Q2
Document Fiscal Year Focus	2019
Current fiscal year end date	--12-31
Entity central index key	0001123494
Entity current reporting status	Yes
Entity filer category	Accelerated Filer
Entity registrant name	HARVARD BIOSCIENCE INC
Entity common stock shares outstanding		38,046,001
Trading Symbol	HBIO
Entity emerging growth	false
Entity small business	true
Entity Shell Company	false

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Current Assets:
Cash and cash equivalents	$ 4,934	$ 8,173
Accounts receivable, net of allowance for doubtful accounts of $370 and $332, respectively	18,388	21,463
Inventories	25,288	25,087
Other receivables and other assets	3,883	3,109
Total current assets	52,493	57,832
Property, plant and equipment, net	5,359	5,898
Operating Lease, Right-of-Use Asset	8,846	0
Deferred income tax assets	210	211
Amortizable intangible assets, net	40,670	44,532
Goodwill	57,239	57,304
Other indefinite lived intangible assets	1,230	1,232
Other assets	191	1,604
Total Assets	166,238	168,613
Current liabilities:
Current portion, long-term debt	2,407	5,982
Current portion, operating lease liabilities	2,295	0
Accounts payable	6,041	7,359
Deferred revenue	3,532	3,820
Accrued income taxes	612	978
Accrued expenses	4,264	5,762
Other liabilities - current	1,710	1,588
Total current liabilities	20,861	25,489
Long-term debt, less current installments	52,414	54,813
Deferred income tax liabilities	2,309	2,301
Other long term liabilities	1,610	3,286
Operating lease liabilities	8,714	0
Total liabilities	85,908	85,889
Commitments and contingencies	0	0
Stockholders Equity Abstract
Preferred stock, par value $0.01 per share, 5,000,000 shares authorized	0	0
Common stock, par value $0.01 per share, 80,000,000 shares authorized; 45,639,892 and 45,124,309 shares issued and 37,894,385 and 37,378,802 shares outstanding, respectively	436	436
Additional paid-in-capital	227,249	226,377
Accumulated deficit	(122,506)	(119,889)
Accumulated other comprehensive loss	(14,181)	(13,532)
Treasury stock at cost, 7,745,507 common shares	(10,668)	(10,668)
Total stockholders' equity	80,330	82,724
Total liabilities and stockholders' equity	$ 166,238	$ 168,613

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parentheticals) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
CONSOLIDATED BALANCE SHEETS
Allowance for doubtful accounts	$ 370	$ 332
Preferred Stock Par value	$ 0.01	$ 0.01
Preferred Stock - Shares Authorized	5,000,000	5,000,000
Common stock par value	$ 0.01	$ 0.01
Common Stock- Shares Authorized	80,000,000	80,000,000
Common Stock- Shares Issued	45,639,892	45,124,309
Common Stock- Shares Outstanding	37,894,385	37,378,802
Treasury Stock common shares	7,745,507	7,745,507

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
CONSOLIDATED STATEMENTS OF OPERATIONS
Revenues	$ 29,584	$ 31,522	$ 57,786	$ 58,281
Cost of revenues	13,629	16,167	25,677	29,657
Gross profit	15,955	15,355	32,109	28,624
Sales and marketing expenses	5,770	6,309	12,076	11,955
General and administrative expenses	4,809	5,258	10,612	10,642
Research and development expenses	2,771	2,758	5,506	5,160
Amortization of intangible assets	1,436	1,412	2,866	2,515
Impairment charges	941	0	941	0
Total operating expenses	15,727	15,737	32,001	30,272
Operating loss	228	(382)	108	(1,648)
Other income (expense):
Foreign exchange	86	345	(93)	(2)
Interest expense, net	(1,376)	(1,483)	(2,781)	(2,377)
Interest income	0	0	0	0
Other expense, net	(70)	(347)	(160)	(3,085)
Other expense, net	(1,360)	(1,485)	(3,034)	(5,464)
Loss from continuing operations before income taxes	(1,132)	(1,867)	(2,926)	(7,112)
Income tax expense (benefit)	(885)	(369)	(309)	236
Loss from continuing operations	(247)	(1,498)	(2,617)	(7,348)
Discontinued operations:
Income (loss) from discontinued operations before income taxes	0	24	0	937
Income tax (benefit) expense	0	(10)	0	(883)
Income (loss) from discontinued operations	0	34	0	1,820
Net loss	$ (247)	$ (1,464)	$ (2,617)	$ (5,528)
Loss per share:
Basic earnings per common share from continuing operations	$ (0.01)	$ (0.04)	$ (70)	$ (210)
Basic earnings (loss) per common share from discontinued operations	0	0	0	0.05
Basic loss per common share	(0.01)	(0.04)	(70)	(150)
Diluted loss per common share from continuing operations	(0.01)	(0.04)	(70)	(210)
Diluted earnings (loss) per common share from discontinued operations	0	0	0	0.05
Diluted loss per common share	$ (0.01)	$ (0.04)	$ (70)	$ (150)
Weighted average common shares:
Basic	37,735,717	36,082,258	37,682,539	35,774,334
Diluted	37,735,717	36,082,258	37,682,539	35,774,334
Comprehensive loss:
Net loss	$ (247)	$ (1,464)	$ (2,617)	$ (5,528)
Foreign currency translation adjustments	(195)	(2,938)	(191)	(1,432)
Derivatives qualifying as hedges, net of tax:
(Loss) gain on derivative instruments designated and qualifying as cash flow hedges	(298)	155	(494)	(99)
Amounts reclassified from accumulated other comprehensive loss to net loss	19	70	36	45
Total comprehensive loss	$ (721)	$ (4,177)	$ (3,266)	$ (7,014)

CONSOLIDATED STATEMENT OF STOCK

CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY - USD ($) $ in Thousands	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Treasury Stock [Member]
Total stockholders' equity at begining of the year, Value at Dec. 31, 2017	$ 80,900	$ 419	$ 218,792	$ (116,967)	$ (10,676)	$ (10,668)
Stock option exercises	1,986	3	1,983
Stock purchase plan	(11)	0	(11)
Vesting of restricted stock units	8	8
Shares withheld for taxes	(603)	(3)	(600)
Stock compensation expense	1,746		1,746
Net income (loss)	(5,528)			(5,528)
Other Comprehensive Income (Loss)	(1,486)				(1,486)
Total stockholders' equity at year end, Value at Jun. 30, 2018	$ 77,012	$ 427	221,910	(122,495)	(12,162)	(10,668)
Beginning balance shares at Dec. 31, 2017	42,764,000	42,764,000
Stock option exercises, shares	719,000	719,000
Stock purchase plan, shares	24,907	25,000
Vesting of restricted stock units, shares	805,000	805,000
Shares withheld for taxes, shares	(211,000)	(211,000)
Ending balance shares at Jun. 30, 2018	44,102,000	44,102,000
Total stockholders' equity at begining of the year, Value at Mar. 31, 2018	$ 79,294	$ 422	220,020	(121,031)	(9,449)	(10,668)
Stock option exercises	1,169	2	1,167
Stock purchase plan	(11)		(11)
Vesting of restricted stock units	3	3
Stock compensation expense	734		734
Net income (loss)	(1,464)			(1,464)
Other Comprehensive Income (Loss)	(2,713)				(2,713)
Total stockholders' equity at year end, Value at Jun. 30, 2018	$ 77,012	$ 427	221,910	(122,495)	(12,162)	(10,668)
Beginning balance shares at Mar. 31, 2018	43,409,000	43,409,000
Stock option exercises, shares	421,000	421,000
Stock purchase plan, shares	25,000	25,000
Vesting of restricted stock units, shares	273,000	273,000
Shares withheld for taxes, shares	(26,000)	(26,000)
Ending balance shares at Jun. 30, 2018	44,102,000	44,102,000
Total stockholders' equity at begining of the year, Value at Dec. 31, 2018	$ 82,724	$ 436	226,377	(119,889)	(13,532)	(10,668)
Stock purchase plan	(89)		(89)
Vesting of restricted stock units	0		0
Shares withheld for taxes	(423)		(423)
Stock compensation expense	1,206		1,206
Net income (loss)	(2,617)			(2,617)
Other Comprehensive Income (Loss)	(649)				(649)
Total stockholders' equity at year end, Value at Jun. 30, 2019	$ 80,330	$ 436	227,249	(122,506)	(14,181)	(10,668)
Beginning balance shares at Dec. 31, 2018	45,124,000	45,124,000
Stock option exercises, shares	3,000	3,000
Stock purchase plan, shares	93,785,000	94,000
Vesting of restricted stock units, shares	554,000	554,000
Shares withheld for taxes, shares	(135,000)	(135,000)
Ending balance shares at Jun. 30, 2019	45,640,000	45,640,000
Total stockholders' equity at begining of the year, Value at Mar. 31, 2019	$ 80,349	$ 436	226,547	(122,259)	(13,707)	(10,668)
Stock purchase plan	(89)		(89)
Vesting of restricted stock units	0		0
Shares withheld for taxes	(2)		(2)
Stock compensation expense	615		615
Net income (loss)	(247)			(247)
Other Comprehensive Income (Loss)	(474)				(474)
Total stockholders' equity at year end, Value at Jun. 30, 2019	$ 80,330	$ 436	$ 227,249	$ (122,506)	$ (14,181)	$ (10,668)
Beginning balance shares at Mar. 31, 2019	45,433,000	45,433,000
Stock purchase plan, shares	94,000	94,000
Vesting of restricted stock units, shares	114,000	114,000
Shares withheld for taxes, shares	(1,000)	(1,000)
Ending balance shares at Jun. 30, 2019	45,640,000	45,640,000

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Cash flows from operating activities:
Net loss	$ (2,617)	$ (5,528)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Stock-based compensation expense	1,206	1,746
Depreciation	972	1,051
Impairment charges	941	0
Gain on sale of Denville	0	(1,251)
Loss on disposal of fixed assets	0	(3)
Amortization Of Catalog Costs	10	14
Provision for allowance for doubtful accounts	368	149
Amortization of Intangible Assets	2,866	2,562
Amortization of deferred financing costs	189	458
Deferrred Income Taxes	(1)	(96)
Changes in operating assets and liabilities:
(Increase) decrease in accounts receivable	2,681	(993)
(Increase) decrease in inventories	(209)	2,139
Decrease (increase) in other receivables and other assets	150	673
Increase (decrease) in trade accounts payable	(1,382)	1,798
Increase in accrued income taxes	(361)	(344)
(Decrease) increase in accrued expenses	(1,371)	(888)
(Decrease) increase in deferred revenue	(288)	2,209
(Decrease) increase in other liabilities	(487)	(1,971)
Net cash provided by operating activities	2,667	1,725
Cash flows used in investing activities:
Additions to property, plant and equipment	(423)	(634)
Additions to catalog costs	(9)	(24)
Acquisitions, net of cash acquired	0	(68,008)
Disposition, net of cash sold	1,020	15,754
Net cash used in investing activities	588	(52,912)
Cash flows provided by (used in) financing activities:
Proceeds from issuance of debt	2,300	68,500
Repayments of debt	(8,503)	(17,247)
Payments of debt issuance costs	0	(1,928)
Net proceeds from (net taxes paid for) issuance of common stock	(334)	1,380
Net cash provided by (used in) financing activities	(6,537)	50,705
Effect of exchange rate changes on cash	43	373
(Decrease) increase in cash and cash equivalents	(3,239)	(109)
Cash and cash equivalents at the begining of period	8,173	5,733
Cash and cash equivalents at the end of period	4,934	5,624
Supplemental cash flow information [Abstract]
Cash paid for interest	2,861	2,448
Cash refunded for income taxes	$ 299	$ (208)

Basis of Presentation and Summa

Basis of Presentation and Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2019
Basis of Presentation and Summary of Significant Accounting Policies Disclosure [Abstract]
Basis of Presentation and Summary of Significant Accounting Policies Disclosure [Text Block]	HARVARD BIOSCIENCE, INC. NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS 1 . Basis of Presentation and Summary of Significant Accounting Policies Basis of Presentation The unaudited consolidated financial statements of Harvard Bioscience, Inc. and its wholly-owned subsidiaries (collectively, Harvard Bioscience or the Company) as of June 30, 2019 and for the three and six months ended June 30, 2019 and 2018 have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (SEC). Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles (U.S. GAAP) have been condensed or omitted pursuant to such rules and regulations. The December 31, 2018 consolidated balance sheet was derived from audited financial statements, but does not include all disclosures required by U.S. GAAP. However, the Company believes that the disclosures are adequate to make the information presented not misleading. These unaudited consolidated financial statements should be read in conjunction with the consolidated f inancial statements and the notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2018 , which was filed with the SEC on March 18, 2019. In the opinion of management, all adjustments, which incl ude normal recurring adjustments necessary to present a fair statement of financial position as of June 30, 2019 , results of operations and comprehensive income (loss) for the three and six months ended June 30, 2019 and 2018 and cash flows for the six months ended June 30, 2019 and 2018 , as applicable, have been made. The results of operations for the three months ended June 30, 2019 are not necessarily indicative of the operating results for the full fis cal year or any future periods. Prior Period Financial Statement Correction of Immaterial Error During the quarter ended March 31, 2019, the Company identified an immaterial misclassification error in the Company’s consolidated balance sheet as of Dece mber 31, 2018. The immaterial misclassification understated current portion, long term debt and overstated long term debt, less current installments. This misclassification, in the amount of approximately $ 4.0 million, related to the classification of th e Company’s excess cash flow payment made to its lenders during the quarter ended March 31, 2019 as long term instead of current on its consolidated balance sheet at December 31, 2018. The misclassification had no impact on total reported debt. Refer to footnote 14 for further details. The Company assessed the materiality of this error on the financial statements for prior periods in accordance with the SEC Staff Accounting Bulletin (SAB) No. 99, Materiality , codified in Accounting Standards Codification (ASC) 250, Presentation of Financial Statements, and concluded that it was not material to any prior annual or interim periods. The Company recorded an adjustment to decrease long term debt, less current installments and increase current portion, long ter m debt in the consolidated balance sheet at December 31, 2018 with no impact on total reported debt. R eclassifications As disclosed in Note 5, on January 22, 2018, the Company sold substantially all the assets of its operating subsidiary, Denville Scientific, Inc. (Denville). The sale of Denville represented a strategic shift that had a major effect on the Company’s operat ions and financial results. As such and pursuant to Accounting Standards Codification (ASC) 205-20 – Presentation of Financial Statements - Discontinued Operations, the operating results of Denville for the three and six months ended June 30, 2018 have been presented in discontinued operations in the consolidated statements of operations. T hese reclassifications and adjustments had no effect on total amounts within the consolidated balance sheet, consolidated statements of operations and comprehensive i ncome ( loss ) , consolidated statements of cash flows for any of the periods presented. Summary of Significant Accounting Policies The accounting policies underlying the accompanying unaudited consolidated financial statements are those set forth in Note 2 to the consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018 , which was filed with the SEC on March 18, 2019. Except for the accounting for leases as noted below there h ave been no material changes in the company’s significant accounting policies during the six months ended June 30, 2019 . Leases The Company accounts for its leases in accordance with ASC 842 Leases . The Company leases office space, manufacturi ng facilities, automobiles and equipment. The Company concludes on whether an arrangement is a lease at inception. This determination as to whether an arrangement contains a lease is based on an assessment as to whether a contract conveys the right to the Company to control the use of identified property, plant or equipment for period of time in exchange for considera tion. Leases with an initial term of 12 months or less are not recorded on the balance sheet. The Company recognizes these lease expenses on a straight line basis over the lease term. As of June 30, 2019 , the Company has assessed its contra cts and concluded that its leases consist of operating leases. Operating leases are included in operating lease right-of-use ( ROU) assets, current portion of operating lease liabilities , and operating lease liabilities in the Company’s consolidated balance sheets. ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recogni zed at commencement date based on the present value of lease payments over the lease term. As most of the Company’s leases do not provide an implicit rate, the Company determines an incremental borrowing rate based on the information available at commencem ent date in determining the present value of lease payments. The incremental borrowing rate represents a significant judgment that is based on an analysis of the Company’s credit rating, country risk, treasury and corporate bond yields, as well as comparis on to the Company’s borrowing rate on its most recent loan. The Company uses the implicit rate when readily determinable. The operating lease ROU asset also includes any lease payments made and excludes lease incentives. Lease expense for lease payments is recognized on a straight-line basis over the lease term. The Company has lease agreements with lease and non-lease components, which are generally accounted for separately. Additionally, for its leases, the Company applies a portfolio approach to effecti vely account for the operating lease ROU assets and liabilities.

Recently Issued Accounting Pron

Recently Issued Accounting Pronouncements	6 Months Ended
	Jun. 30, 2019
Recently Issued Accounting Pronouncements [Abstract]
Recently Issued Accounting Pronouncements Disclosure [Text Block]	2 . Recently Issued Accounting Pronouncements In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which amends the impairment model by requiring entities to use a forward-looking approach based on expected losses rather than incurred losses to estimate credit losses on certain types of financial instruments, including trade receivables. This may resul t in the earlier recognition of allowances for losses. The ASU is effective for public entities for fiscal years beginning after December 15, 2019, with early adoption permitted. In May 2019, the FASB issued ASU No. 2019-05, Financial Instruments – Credit Losses (Topic 326): Targeted Transition Relief , which provided additional implementation guidance on the previously issued ASU. Management has not yet completed its assessment of the impact of the new standard on the Company’s Consolidated Financial Statem ents. Currently, the Company believes that the most notable impact of this ASU will relate to its processes around the assessment of the adequacy of its allowance for doubtful accounts on trade accounts receivable and the recognition of credit losses. In August 2018, the FASB issued ASU No. 2018-14, Disclosure Framework—Changes to the Disclosure Requirements for Defined Benefit Plans , which amends ASC 715 to add, remove and clarify disclosure requirements related to defined benefit pension and other postre tirement plans. The ASU is effective for public entities for fiscal years beginning after December 15, 2020, with early adoption permitted. Management has not yet completed its assessment of the impact of the new standard on the Company’s Consolidated Fina ncial Statements. In April 2019, the FASB issued ASU No. 2019-04, Codification Improvements to Topic 815, Derivatives and Hedging , which updates certain guidance previously issued in ASU No. 2017-12, Derivatives and Hedging (Topic 815) . The ASU is effect ive as of January 1, 2020, which is the beginning of the first annual period beginning after the issuance of the ASU for public entities that have adopted ASU No. 2017-12. Entities may elect either to retrospectively apply all amendments in the ASU or to p rospectively apply all amendments as of the date of adoption of the ASU. Management has not yet completed its assessment of the impact of the new standard on the Company’s Consolidated Financial Statements. Recently Adopted Accounting Pronouncements In August 201 7, the FASB issued ASU No. 2017-12, Derivatives and Hedging (Topic 815) which amends the hedge accounting recognition and presentation requirements in ASC 815 , Derivatives and Hedging . The Board’s objectives in issuing the ASU are to (1) improve the transparency and understandability of information conveyed to financial statement users about an entity’s risk management activities by better aligning the entity’s financial reporting for hedging relationships with those risk manag ement activities and (2) reduce the complexity of and simplify the application o f hedge accounting by preparers. The ASU is effective for annual reporting periods, including interim periods within those annual reporting periods, beginning after December 15 , 201 8. The Company adopted this guidance as of January 1, 2019, and it did not have a material impact on its consolidated financial position, results of operations and cash flows. In February 2016, the FASB issued ASU No. 2016-02, Leases , which is intend ed to improve financial reporting about leasing transactions. The update requires a lessee to record on its balance sheet the assets and liabilities for the rights and obligations created by lease terms of more than 12 months. The update is effective for f iscal years beginning after December 15, 2018. A modified retrospective transition approach is required for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain prac tical expedients available. T he Company elected to utilize a practical expedient in its method of adoption of the standard and adopted the guidance as of January 1, 2019 . Under this expedient, which is a “current-period adjustment method,” the Company app lied ASC 842 as of January 2019 and recognized operating lease liabilities of $ 11.7 million and right of use assets of $ 9.4 million for all leases with lease terms of more than 12 months. There was no impact to retained earnings as of that date. In additio n, the Company adopted the guidance by electing the following practical expedients: (1) the Company did not reassess whether any expired or existing contracts contained leases, (2) the Company did not reassess the lease classification for any expired or ex isting leases, and (3) the Company excluded variable payments from the lease contract consideration and recorded those as incurred. The Company’s future commitments under lease obligations and additional disclosures are summarized in Note 12.

Accumulated Other Comprehensive

Accumulated Other Comprehensive Income Loss	6 Months Ended
	Jun. 30, 2019
Accumulated Other Comprehensive Income [Abstract]
Accumulated Other Comprehensive Income Disclosure [Text Block]	3. Accumulated Other Comprehensive Loss Changes in each component of accumulated other comprehensive loss, net of tax are as follows: Foreign currency Derivatives translation qualifying as Defined benefit (in thousands) adjustments hedges pension plans Total Balance at December 31, 2018 $ (12,630) $ (170) $ (732) $ (13,532) Other comprehensive income (loss) before reclassifications (191) (494) - (685) Amounts reclassified from AOCI - 36 - 36 Other comprehensive income (loss) (191) (458) - (649) Balance at June 30, 2019 $ (12,821) $ (628) $ (732) $ (14,181)

Acquisitions

Acquisitions	6 Months Ended
	Jun. 30, 2019
Acquisition Disclosure [Abstract]
Acquisitions Disclosure [Text Block]	4 . Acquisition On January 31, 2018, the Company acquired all of the issued and outstanding shares of Data Sciences International, Inc. (DSI), a Delaware corporation , for approximately $ 7 1.1 million. The Company funded the acquisition from its existing cash balances, excess proceeds from the Denville Transaction discussed in Note 5, and proceeds from the Financing Agreement discussed in Note 14 . DSI, a St. Paul, Minnesota-based life science research company, is a recognized leader in physiologic monitoring focused on delivering preclinical products, systems, services and solutions to its customers. Its customers include pharmaceutical and biotechnology companies, as well as contract research organizations, academic labs and government researchers. This acquisition diversifies the Company’s customer base into the biopharmaceutical and contract research organization markets. The aggregate purchase price for this acquisition was allocated to ta ngible and intangible net assets acquired as follows: (in thousands) Tangible assets $ 34,010 Liabilities assumed (11,949) Net assets 22,061 Goodwill and intangible assets: Goodwill 21,865 Amortizable intangible assets: Trade name 3,524 Developed technology 25,570 Customer relationships 9,837 In-process research and development 1,387 Total amortizable intangible assets 40,318 Deferred tax liabilities, net (13,120) Total goodwill and intangible assets, net of tax 49,063 Acquisition purchase price $ 71,124 Tangible assets and liabilities assumed, as referenced above, consisted of the following: Cash acquired $ 2,576 Accounts receivable, net 5,069 Inventories 11,512 Other current assets 810 Property, plant and equipment, net 3,574 Deferred income tax assets, net 10,469 Tangible assets $ 34,010 Accounts payable and accrued liabilities $ 6,001 Deferred revenue including customer advances 2,976 Other long term liabilities 2,972 Liabilities assumed $ 11,949 The Company finalized the purchase price allocation for DSI as of December 31, 2018. T he weighted-average amortization periods for definite-lived intangible assets acquired was 9.4 years for tradenames, 8.2 years for developed technology, 12.4 years for customer relationships and 7.4 years for in-process research and development assets. The weighted average amortization period for all definite-lived inta ngible assets acquired was 9.3 years. Goodwill recorded as a result of the acquisition of DSI is not deductible for tax purposes. The results of operations for DSI have been included in the Company’s consolidated financial statements from t he date of acquisition. T he revenues of DSI included in the Company’s consolidated statement of operations from the date of acquisition to June 30 , 2018 were approximately $ 18 . 2 million. The net loss of DSI included in the Company’s consolidated statement of operations for the same period was approximately $ 1.7 million. Included in the net loss for the six months ended June 30, 2018 was a $ 3.7 million charge recognized in cost of revenues related to purchase accounting inventory fair value step up amortization. The total inventory fair value step up was valued at $ 3.8 million and was recognized into cost of revenues over one inventory turn, or approxi mately five and a half months. Also included in the net loss of DSI for that period was $ 1 . 8 mil lion of intangible asset amortization expense. The following consolidated pro forma information is based on the assumption that was used at the time of the acquisition of DSI . Accordingly, the historical results have been adjuste d to reflect amortization expense, interest expense and other purchase accounting adjustments that would have been recognized on such a pro forma basis. The pro forma information is presented for comparative purposes only and is not necessarily indicative of the financ ial position or results of operations which would have been reported had the Company completed the acquisition during these periods or which might be reported in the future. Six Months Ended June 30, 2018 (in thousands) Pro Forma Revenues $ 61,671 Income (loss) from continuing operations (392) Direct acquisition costs recorded in other expense, net in the Company’s consolidated statements of operations were $ 2.6 million f or the six months ended June 30, 2018 .

Discontinued Operations

Discontinued Operations	6 Months Ended
	Jun. 30, 2019
Discontinued Operations [Abstract]
Discontinued Operations Disclosure [Text Block]	5. Discontinued Operations On January 22, 2018, the Company sold substantially all the assets of its wholly owned subsidiary, Denville , for approximately $ 20.0 million, which included a $ 3.0 million earn-out provision (the Denville Transaction). Upon the closing of the transaction, the Company received $15.7 million. The $ 3.0 million earn-out provision represented consideration that was contingent on Denville achieving certain performance metrics with respect to 2018 and 2019 ( The following table is a reconciliation of the major line items of income from discontinued operations presented within the Company’s consolidated statements of operations for the three and six months ended June 30 , 2018 . Three Months Ended Six Months Ended June 30, June 30, 2018 2018 (in thousands) Revenues $ - $ 893 Cost of revenues - (534) Operating and other expenses - (673) Gain on disposal of discontinued operations 24 1,251 Income from discontinued operations before income taxes 24 937 Income tax benefit (10) (883) Income from discontinued operations $ 34 $ 1,820 During the three months ended June 30, 2019, the Company received a release of an escrow am ount of $1.0 million related to the Denville Transaction, which is included in the investing cash flows for disposition in the Company’s consolidated statements of cash flows for the six months ended June 30, 2019. Total operating cash flows for Denville in the Company’s consolidated statements of cash flows for the six months ended June 30, 2018, were immaterial.

Goodwill and Other Intangible A

Goodwill and Other Intangible Assets	6 Months Ended
	Jun. 30, 2019
Goodwill And Other Intangible Assets Disclosure [Abstract]
Goodwill And Other Intangible Assets Disclosure [Text Block]	6 . Goodwill and Other Intangible Assets Intangible assets consist of the following: Weighted Average June 30, 2019 December 31, 2018 Life (a) (in thousands) Amortizable intangible assets: Gross Accumulated Amortization Gross Accumulated Amortization Existing technology $ 41,205 $ (18,004) $ 41,268 $ (16,215) 6.6 Years Trade names 7,809 (3,182) 7,828 (2,861) 7.2 Years Distribution agreements/customer relationships 22,603 (10,147) 22,657 (9,509) 10.2 Years In-process research and development 446 (60) 1,387 (30) 6.4 Years Patents 211 (211) 211 (204) - Years Total amortizable intangible assets 72,274 $ (31,604) 73,351 $ (28,819) Indefinite-lived intangible assets: Goodwill 57,239 57,304 Other indefinite-lived intangible assets 1,230 1,232 Total goodwill and other indefinite-lived intangible assets 58,469 58,536 Total intangible assets, gross $ 130,743 $ 131,887 (a) Weighted average life as of June 30, 2019. The change in the carrying amount of goodwill for the six months ended June 30, 2019 is as follows: (in thousands) Balance at December 31, 2018 $ 57,304 Effect of change in currency translation (65) Balance at June 30, 2019 $ 57,239 Intangible asset amortization expense from continuing operations was $ 1.4 million for the three months ended June 30, 2019 and 2018 , respectively . Intangible asset amortization expense from continuing operations was $2.9 million and $2.5 million for the six months ended June 30, 2019 and 2018 , respectively. Amortization expense of existing amortizable intangible assets is cur rently estimated to be $ 5.6 million for the year ending December 31, 2019 , $ 5.6 million for the year ending December 31, 2020 , $ 5.6 million for the year ending December 31, 2021 , $ 5.5 million fo r the year ending December 31, 2022 , $ 5.4 million for the year ending December 31, 2023 , and $5.3 million for the year ending December 31, 2024 . During the three months ended June 30, 2019, the Company recognized an impairment charge of $0.9 million related to certain of its in-process research and development intangible assets as a result of the on-going evaluation of its capitalized research and development activities. There was no impairment charge recognized during the three and six months ended June 30, 2018.

Inventories

Inventories	6 Months Ended
	Jun. 30, 2019
Inventories Disclosure [Abstract]
Inventories Disclosure [Text Block]	7 . Inventories Inventories consist of the following: June 30, December 31, 2019 2018 (in thousands) Finished goods $ 6,729 $ 6,936 Work in process 4,101 3,667 Raw materials 14,458 14,484 Total $ 25,288 $ 25,087

Property, Plant and Equipment

Property, Plant and Equipment	6 Months Ended
	Jun. 30, 2019
Property, Plant and Equipment Disclosure [Abstract]
Property, Plant and Equipment Disclosure [Text Block]	8 . Property , Plant and Equipment As of June 30, 2019 and December 31, 2018 , p roperty, plant and equipment consist of the following: June 30, December 31, 2019 2018 (in thousands) Land, buildings and leasehold improvements $ 2,527 $ 2,468 Machinery and equipment 9,914 9,678 Computer equipment and software 9,814 9,685 Furniture and fixtures 1,406 1,390 Automobiles 114 115 23,775 23,336 Less: accumulated depreciation (18,416) (17,438) Property, plant and equipment, net $ 5,359 $ 5,898

Related Party Transactions

Related Party Transactions	6 Months Ended
	Jun. 30, 2019
Related Party Transactions [Abstract]
Related Party Transactions Disclosure [Text Block]	9 . Related Party Transactions As part of the acquisitions of Multi Channel Systems MCS GmbH (MCS) and Triangle BioSystems , Inc. (TBSI) in 2014, the Company signed lease agreements with the former owners of these acquired companies. The principals of such former owners of MCS and TBSI were employees of the Company as of June 30, 2019 and 2018. Pursuant to these lease agreeme nts, the Company made rent payments of approximately $ 89 thousand and $ 81 thousand to these former owners for the three months ended June 30, 2019 and 2018, respectively. The Company made rent payments of approximately $ 178 thousand and $ 171 thousand to th ese former owners for the six months ended June 30, 2019 and 2018, respectively.

Warranties

Warranties	6 Months Ended
	Jun. 30, 2019
Warranties Disclosure [Abstract]
Warranties Disclosure [Text Block]	10 . Warranties Warranties are estimated and accrued at the time revenues are recorded. A rollforward of the Company’s product warranty accrual is as follows: Beginning (Payments)\ Ending Balance Credits Additions Balance (in thousands) Year ended December 31, 2018 $ 246 (37) 182 $ 391 Six months ended June 30, 2019 $ 391 (79) 6 $ 318

Employee Benefit Plans

Employee Benefit Plans	6 Months Ended
	Jun. 30, 2019
Employee Benefit Plans Disclosure [Abstract]
Employee Benefit Plans Disclosure [Text Block]	11 . Employee Benefit Plans The Company’s subs idiary in the United Kingdom, Biochrom Limited, maintain s contributory, defined benefit pension plans for substantially all of its employees. These defined benefit pension plans have been closed to new employees since 2014, as well as closed to the future accrual of benefits for existing employees. The components of the Company’s defined benefit pension expense were as follows: Three Months Ended Six Months Ended June 30, June 30, 2019 2018 2019 2018 (in thousands) Components of net periodic benefit cost: Interest cost $ 123 $ 118 $ 255 $ 250 Expected return on plan assets (170) (184) (352) (388) Net amortization loss 71 52 147 110 Net periodic benefit cost (income) $ 24 $ (14) $ 50 $ (28) For the three months ended June 30, 2019 and 2018 , the Company contributed $ 0.2 million, for both periods, to its defined benefit pension plans. For the six months ended June 30, 2019 and 2018 , the Compan y contributed $0.4 million and $0.4 million, respectively to its defined benefit pension plans. The Company expects to contribute approximately $ 0.3 million to its defined benefit pension plans during the remainder of 2019 . The Com pany had an underfunded pension liability of approximately $ 0.9 million as of June 30, 2019 and December 31 , 2018 included in the other long term liabilities line item in the consolidated balance sheets.

Leases

Leases	6 Months Ended
	Jun. 30, 2019
Leases [Abstract]
Leases [Text Block]	12 . Leases The Company has noncancelable operating leases for office , manufacturing facilities, warehouse space , automobiles and equipment expiring at various dates through 2023 and thereafter. As discussed in Footnote 1, the Company adopted ASC 842 as of January 1, 2019, using a current period adjustment method. In accordance with this method, the Company recognized a right of use asset of $ 9.4 million and an operating lease liability of $ 11.7 million as of January 1, 2019. As a result of using the current period adjustment method, the lease expense for six months ended June 30, 2019 and 2018 was recognized under ASC 842, and ASC 840, the previous standard, respectively. The components of lease expense for the three and six months ended June 30, 2019 are as follows: Three Months Ended Six Months Ended June 30, 2019 June 30, 2019 (in thousands) (in thousands) Operating lease cost $ 515 $ 1,038 Short term lease cost 51 127 Sublease income (103) (205) Total lease cost $ 463 $ 960 Supplemental cash flow information related to the Company's operating leases was as follows Six Months Ended June 30, 2019 (in thousands) Cash paid for amounts included in the measurement of lease liabilities Operating cash flows from operating leases $ 1,367 Right-of-use assets obtained in exchange for lease obligations Operating leases $ - Supplemental balance sheet information related to the Company's operating leases was as follows: June 30, 2019 (in thousands) Operating lease right-of use assets $ 8,846 Current portion, operating lease liabilities $ 2,295 Operating lease liabilities, long term 8,714 Total operating lease liabilities $ 11,009 Weighted average remaining lease term 8.5 years Weighted average discount rate 9.2% Rent payments for continuing operations were approximately $ 1.4 million for the six months ended June 30, 2018 . Future minimum lease payments for operating leases, with initial or remaining terms in excess of one year at June 30, 2019 , are as follows: Operating Leases (in thousands) 2020 $ 2,295 2021 2,108 2022 1,852 2023 1,804 2024 1,798 Thereafter 6,543 Total lease payments 16,400 Less interest (5,391) Total operating lease liabilities $ 11,009

Capital Stock

Capital Stock	6 Months Ended
	Jun. 30, 2019
Capital Stock Disclosure [Abstract]
Capital Stock Disclosure [Text Block]	13 . Capital Stock Common Stock The Company has 80.0 million shares of common stock authorized for issuance. As of June 30, 2019 , the Company had 37.9 million shares of common stock issued and outstanding . Preferred Stock The Company’s Board of Directors has the authority to issue up to 5.0 million shares of preferred stock and to determine the price, privileges and other terms of the shares. The Board of Directors may exercise this authority without any further approval of stockholders. As of June 30, 2019 , the Company had no preferred stock issued or outstanding . Employee Stock Purchase Plan (as amended, the ESPP) In 2000, the Company approved the ESPP . Under this ESPP , participating employees can authorize the Company to withhold a portion of their base pay during consecutive six-month payment periods for the purchase of shares of the Company’s common stock. At the conclusion of the period, participating employees can purchase shares of the Company’s common stock at 85% of the lower of the fair market value of the Company’s common stock at the beginning or end of the period. Shares are iss ued under the ESPP for the six-month periods ending June 30 and December 31. As of June 30, 2019 , 1,400,000 shares of common stock are authorized for issuance , of which 984,547 shares were iss ue d. There were 93,785 and 24,907 shares issued under the ESPP during the six months ended June 30, 2019 and 2018 , respectively. Stock Option and Equity Incentive Plans Third Amended and Restated 2000 Stock Option and Incentive Plan (as amended, the Third A&R Plan) The Third Amendment to the Third A&R Plan (the Amendment) was adopted by the Board of Directors on April 2, 2018. Such Amendment was approved by the stockholders at the Company’s 2018 Annual Meeting of Stockholders. Pursuant to the Amendment, the aggregat e number of shares authorized for issuance under the Third A&R Plan was increased by 3,400,000 shares to 20,908,929 . Restricted Stock Units with a Market Condition (the Market Condition RSUs) On May 24, 2018, the Compensation Committee of the Board o f Directors of the Company approved and granted deferred stock awards of Market Condition RSUs (the 2018 Market Condition RSUs) to certain members of the Company’s management team under the Third A&R Plan . The vesting of the 2018 Market Condition RSUs is b ased on a graded-vesting schedule (one third at the end of each year for three years) and linked to the achievement of a relative total shareholder return of the Company’s common stock from May 24, 2018 to the earlier of (i) May 24, 2019 or (ii) upon a cha nge of control (measured relative to the NASDAQ Biotechnology index and based on the 20-day trading average price before each such date). As of June 30, 2019 , t he target number of these restricted stock units that may be earned is 7,556 shares ; the maximum amount is 150% of the target number. On March 7, 2019, the Compensation Committee of the Board of Directors of the Company approved and granted deferred stock awards of Market Condition RSUs (the 2019 Market Condition RSUs) to certain member s of the Company’s management team under the Third A&R Plan . The vesting of the 2019 Market Condition RSUs is based on a graded-vesting schedule (one third at the end of each year for three years) and linked to the achievement of a relative total sharehold er return of the Company’s common stock from March 7, 2019 to the earlier of (i) March 7, 2020 or (ii) upon a change of control (measured relative to the NASDAQ Biotechnology index and based on the 20-day trading average price before each such date). As of June 30, 2019 , t he target number of these restricted stock units that may be earned is 56,517 shares; the maximum amount is 150% of the target number. Stock-Based Payment Awards The Company accounts for stock-based payment awards in accordance with the provisions of FASB ASC 718, which requires it to recognize compensation expense for all stock-based payment awards made to employees and directors including stock options, restricte d stock units, Market Condition RSUs and employee stock purchases related to the ESPP. The Company has elected as an accounting policy to account for forfeitures for service based awards as they occur, with no adjustment for estimated forfeitures. Stock o ption and restricted stock unit activity under the Company’s Third A&R Plan for the six months ended June 30, 2019 was as follows: Stock Options Restricted Stock Units Market Condition RSU's Weighted Stock Average Restricted Market Options Exercise Stock Units Grant Date Condition RSU's Grant Date Outstanding Price Outstanding Fair Value Outstanding Fair Value Balance at December 31, 2018 1,956,732 $ 4.25 1,233,762 $ 3.36 116,944 $ 4.19 Granted 587,909 3.73 599,977 3.19 75,514 4.16 Exercised (2,500) 3.25 - - - - Expired (2,635) 2.28 - - - - Vested (RSUs) - - (550,200) 3.46 (3,778) 4.19 Cancelled / forfeited (356,649) 4.03 (229,883) 3.48 (124,607) 4.19 Balance at June 30, 2019 2,182,857 $ 4.15 1,053,656 $ 3.19 64,073 $ 4.16 Three Months Ended Six Months Ended June 30, June 30, 2019 2018 2019 2018 Volatility 47.76 % 42.31 % 45.69 % 42.31 % Risk-free interest rate 1.86 % 2.82 % 2.42 % 2.82 % Expected holding period (in years) 4.70 years 4.95 years 4.73 years 4.95 years Dividend yield - % - % - % - % Six Months Ended June 30, 2019 2018 Volatility 48.00 % 44.02 % Risk-free interest rate 2.50 % 2.27 % Correlation coefficient 0.27 % 0.07 % Dividend yield - % - % The Company used historical volatility to calculate the expected volatility for each grant as of the grant date . Historical volatility was determined by calculating the mean reversion of the daily adjusted closing stock price. The risk-free interest rate assumption is based upon observed U.S. Treasury bill interest rates (risk-free) appropriate for the term of the Co mpany’s stock options and Market Condition RSUs. The expected holding period of stock options represents the period of time options are expected to be outstanding and is based on historical experience. The vesting period ranges from one to four years and t he contractual life is ten years. The correlation coefficient, used to value the Market Condition RSUs, represents the way in which entities move in relation to the NASDAQ Biotechnology index as a whole. Stock- based c ompensation expense related to stock o ptions, restricted stock units , Market Condition RSUs and the ESPP for the three and six months ended June 30, 2019 and 2018 was allocated as follows: Three Months Ended Six Months Ended June 30, June 30, 2019 2018 2019 2018 (in thousands) Cost of revenues $ 8 $ 15 $ 21 $ 26 Sales and marketing 36 102 29 226 General and administrative 529 576 1,080 1,273 Research and development 42 41 76 71 Discontinued operations - - - 150 Total stock-based compensation $ 615 $ 734 $ 1,206 $ 1,746 The Company did not capitalize any stock-based compensation. Earnings per share Basic earnings per share is based upon net income divided by the number of weighted average common shares outstanding during the period. The calculation of diluted earnings per share assumes conversion of stock options, restricted stock units and Market Condition RSU s into common stock using the treasury method. The weighted av erage number of shares used to compute basic and diluted earnings per share consists of the following: Three Months Ended Six Months Ended June 30, June 30, 2019 2018 2019 2018 Basic 37,735,717 36,082,258 37,682,539 35,774,334 Effect of assumed conversion of employee and director stock options, restricted stock units and Market Condition RSUs - - - - Diluted 37,735,717 36,082,258 37,682,539 35,774,334 Excluded from the shares used in calculating the diluted earnings per common share in the above table are options, restricted stock units and Market Condition RSUs of approximately 3,300,586 and 4,737,057 shares of common stock for th e six months ended June 30, 2019 and 2018 , respectively, as the impact of these shares would be anti-dilutive.

Long Term Debt

Long Term Debt	6 Months Ended
	Jun. 30, 2019
Long Term Debt Disclosure [Abstract]
Long Term Debt Disclosure [Text Block]	14. Long Term Debt On January 22, 2018, in connection with the closing of the Denville Transaction, the Company terminated the Third Amended and Restated Credit Agreement (the Credit Agreement), among the Company, Brown Brothers Harriman & Co. and each of the other lenders p arty thereto, and Bank of America, as administrative agent. All outstanding amounts under the agreement were repaid in full using a portion of the proceeds of the Denville Transaction. At the time of repayment, there was approximately $11.9 million outstan ding. On January 31, 2018, the Company entered into a financing agreement by and among the Company and certain subsidiaries of the Company parties thereto, as borrowers (collectively, the Borrower), certain subsidiaries of the Company parties thereto, as guarantors, various lenders from time to time party thereto (the Lenders), and Cerberus Business Finance, LLC, as collateral agent and administrative agent for the Lenders (the Financing Agreement). On August 16, 2018, the Company and Cerberus Business Fin ance, LLC entered into a First Amendment to the Financing Agreement, which such amendment modified certain provisions related to the borrowing base and reporting, among other things. The Financing Agreement provided for senior secured credit facilities (the Senior Secured Credit Facilities) comprised of a $64.0 million term loan and up to a $25.0 million revolving line of credit. The proceeds of the term loan and $4.8 million of advances under the revolving line of credit were used to fund a portion of t he DSI acquisition, and to pay fees and expenses related thereto and the closing of the Senior Secured Credit Facilities. In addition, the revolving facility is available for use by the Company and its subsidiaries for general corporate and working capital needs, and other purposes to the extent permitted by the Financing Agreement. The Senior Secured Credit Facilities have a maturity of five years. Commencing on March 31, 2018, the outstanding term loans began to amortize in equal quarterly installments equal to $0.4 million per quarter on such date and during each of the next three quarters thereafter, $0.6 million per quarter during the next four quarters thereafter and $0.8 million per quarter thereafter, with a balloon payment at maturity. Furthermor e, within ten days of the Company’s delivery of its audited annual financial statements each year, the term loans are permanently reduced pursuant to certain mandatory prepayment events including an annual “excess cash flow sweep” of 50% of the consolidate d excess cash flow; provided that, in any fiscal year, any voluntary prepayments of the term loans shall be credited against the Company’s “excess cash flow” prepayment obligations on a dollar-for-dollar basis for such fiscal year . During the three months ended March 31 , 2019, the Company made an excess cash flow payment of $ 4.0 million as required by the Financing Agreement . Additionally, during the three months ended June 30, 2019, the Company made a payment, as required by the Financing Agreement, of $1.0 million in connection with the release of an escrow am ount associated with the Denville Transaction discussed in Note 5. The obligations of the Borrower under the Senior Secured Credit Facilities are unconditionally guaranteed by the Company and certain of the Company’s existing and subsequently acquired or organized subsidiaries. The Senior Secured Credit Facilities and related guarantees are secured on a first-priority basis (subject to certain liens permitted under the Financing Agreement) by a lien on substantially all the ta ngible and intangible assets of the Borrower and the subsidiary guarantors, including all of the capital stock held by such obligors (subject to a 65% limitation on pledges of capital stock of foreign subsidiaries), subject to certain exceptions. Interes t on all loans under the Senior Secured Credit Facilities is paid monthly. Borrowings under the Financing Agreement accrue interest at a per annum rate equal to, at the Borrower’s option, a base rate plus 4.75 % or a London Interbank Offered Rate ( LIBOR) ra te plus 6.25 % . The loans are also subject to a 1.25 % interest rate floor for LIBOR loans and a 4.25 % interest rate floor for base rate loans. The Financing Agreement contains customary representations and warranties and affirmative covenants applicable t o the Company and its subsidiaries and also contains certain restrictive covenants, including, among others, limitations on the incurrence of additional debt, liens on property, acquisitions and investments, loans and guarantees, mergers, consolidations, l iquidations and dissolutions, asset sales, dividends and other payments in respect of the Company’s capital stock, prepayments of certain debt, transactions with affiliates and modifications of organizational documents, material contracts, affiliated pract ice agreements and certain debt agreements. The Financing Agreement also contains customary events of default. As of June 30, 2019 , the Company was in compliance with all financial covenants contained in the Financing A greement, was subject to covenant and w orking capital borrowing restrictions and had available borrowing capacity under its Financing Agreement of $ 9.5 million. As of June 30, 2019 , the w eighted effective interest rate, net of the impact of t he Company’s interest rate swap, on its term loan was 8.85%. T he carrying value of the debt approximates fair value because the interest rate under the obligation ap proximates market rates of interest available to the Company for similar instruments. As of June 30, 2019 and December 31, 2018 , the Company’s borrowings were comprised of: June 30, December 31, 2019 2018 (in thousands) Long-term debt: Term loan $ 56,197 $ 62,400 Total unamortized deferred financing costs (1,376) (1,605) Total debt 54,821 60,795 Less: current installments (2,800) (6,383) Current unamortized deferred financing costs 393 401 Long-term debt $ 52,414 $ 54,813

Derivatives

Derivatives	6 Months Ended
	Jun. 30, 2019
Derivatives [Abstract]
Derivatives Disclosure [Text Block]	15 . Derivatives The Company uses interest -rate -related derivative instruments to manage its exposure related to changes in interest rates on its variable - rate debt instruments. The Company does not enter into derivative instruments for any purpose other than cash flow hedging. The Company does not speculate using derivative instruments. By using derivative financial instruments to hedge exposures to change s in interest rates, the Company exposes itself to credit risk and market risk. Credit risk is the failure of the counterparty to perform under the terms of the derivative contract. When the fair value of a derivative contract is positive, the counterparty owes the Company, which creates credit risk for the Company. When the fair value of a derivative contract is negative, the Company owes the counterparty and, therefore, the Company is not exposed to the counterparty’s credit risk in those circumstances. T he Company minimizes counterparty credit risk in derivative instruments by entering into transactions with carefully selected major financial institutions based upon their credit profile. Market risk is the adverse effect on the value of a derivative i nstrument that results from a change in interest rates. The market risk associated with interest -rate contracts is managed by establishing and monitoring parameters that limit the types and degree of market risk that may be undertaken. The Company assesse s interest rate risk by continually identifying and monitoring changes in interest rate exposures that may adversely impact expected future cash flows and by evaluating hedging opportunities. The Company maintains risk management control systems to monitor interest rate risk attributable to both the Company’s outstanding or forecasted debt obligations as well as the Company’s offsetting hedge positions. The risk management control systems involve the use of analytical techniques, including cash flow sensiti vity analysis, to estimate the expected impact of changes in interest rates on the Company’s future cash flows. The Company uses variable -rate LIBOR debt to finance its operations. The debt obligations expose the Company to variability in interest payment s due to changes in interest rates. Management believes that it is prudent to limit the variability of a portion of its interest payments. To meet this objective, management enters into LIBOR based interest rate swap agreements to manage fluctuations in ca sh flows resulting from changes in the benchmark interest rate of LIBOR. These swaps change the variable -rate cash flow exposure on the debt obligations to fixed cash flows. Under the terms of the interest rate swaps, the Company receives LIBOR based vari able interest rate payments and makes fixed interest rate payments, thereby creating the equivalent of fixed-rate debt for the notional amount of its debt hedged. As disclosed in Note 14 , on January 31, 2018, the Company entered into a Financing Agreeme nt comprised of a $64.0 million term loan and up to a $25.0 million revolving line of credit. Shortly after entering into th e Financing Agreement , the Company entered into an interest rate swap contract with PNC Bank with a notional amount of $36.0 million and a termination date of January 1, 2023 in order to hedge the risk of changes in the effective benchmark interest rate (LIBOR) associated with the Company’s Term Loan. T he swap contract converted specific variable-rate debt into fixed-rate debt and fixed the LIBOR rate associated with a portion of the term loan under the Financing Agreement at 2.72%. The interest rate swap was designated as a cash flow hedge instrument in accordance with ASC 815 “Derivatives and Hedging”. The following table presents th e notional amount and fair value of the Company ’ s derivative instrument s as of June 30, 2019 and December 31, 2018 June 30, 2019 Notional Amount Fair Value (a) Derivatives designated as hedging instruments under ASC 815 Balance sheet classification (in thousands) Interest rate swaps Other assets (long term liabilities) $ 31,591 $ (628) December 31, 2018 Notional Amount Fair Value (a) Derivatives designated as hedging instruments under ASC 815 Balance sheet classification (in thousands) Interest rate swaps Other assets (long term liabilities) $ 34,090 $ (170) (a) See Note 16 for the fair value measurements related to these financial instruments. All of the Company’s derivative instruments are designated as hedging instruments. The Company has structured its interest rate swap agreements to be 100% effective and as a result, there was no impact to earnings resulting from hedge ineffectiveness. Changes in the fair value of interest rate swaps designated as hedging instruments that effectively offset the variability of cash flows associate d with variable -rate, long -term debt obligations are reported in accumulat ed other comprehensive income (AOCI ). These amounts subsequently are reclassified into interest expense as a yield adjustment of the hedged interest payments in the same period in wh ich the related interest affects earnings. The Company’s interest rate swap agreement was deemed to be fully effective in accordance with ASC 815, and, as such, unrealized gains and losses related to these derivatives were recorded as AOCI. The following table summarizes the effect of derivatives designated as cash flow hedging instruments and their classification within comprehensive loss for the three and six months ended June 30, 2019 and 2018 : Derivatives in Hedging Relationships Amount of gain (loss) recognized in OCI on derivative (effective portion) Three months ended Six Months Ended June 30, June 30, 2019 2018 2019 2018 (in thousands) Interest rate swaps $ (298) $ 155 $ (494) $ (99) The following table summarizes the reclassifications out of accumulated other comprehensive loss for the three and six months ended June 30, 2019 and 2018 : Details about AOCI Components Amount reclassified from AOCI into income (effective portion) Three Months Ended Six Months Ended Location of amount reclassified from AOCI June 30, June 30, 2019 2018 2019 2018 into income (effective portion) (in thousands) Interest rate swaps $ 19 $ 70 $ 36 $ 45 Interest expense As of June 30, 2019 , $ 0.2 million of deferred losses on derivative instruments accumulated in AOCI are expected to be reclassified to earnings during the next twelve months. Transactions and events expected to occur over the next twelve months that will necessitate reclassifying these der ivatives’ losses to earnings include the repricing of variable -rate debt.

Fair Value Measurements

Fair Value Measurements	6 Months Ended
	Jun. 30, 2019
Fair Value Disclosures [Abstract]
Fair Value Disclosures [Text Block]	The weighted average fair value of the options granted under the Third A&R Plan during the three months ended June 30, 2019 and 2018 was $0.97 and $1.81, respectively, and during the six months ended June 30, 2019 and 2018 was $1.56 and $1.81, respectively. The following assumptions were used to estimate the fair value, using the Black-Scholes option pricing model, of stock options granted during the th ree and six months ended June 30, 2019 : The weighted average fair value of the 2019 Market Condition RSUs which were granted under the Third A&R Plan during the three months ended March 31, 2019 was $4.16. There were no Market Condition RSUs granted under the Third A&R Plan during the three months ended June 30, 2019 . The weighted average fair value of the 2018 Market Condition RSUs which were granted under the Third A&R Plan during the three months ended June 30, 2018 was $4.19. There were no Market Condition RSUs granted under the Third A&R Plan during the three months ended March 31, 2018 . The following assumptions were used to estimate the fair value, using a Monte-Carlo valuation simulation, of the Market Condition RSUs granted during the six months ended June 30, 2019 and 2018 : 16 . Fair Value Measurements Fair value measurement is defined as the price that would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. A fair value hierarchy is established, which prioritizes the inputs used in measuring fair value into three broad levels as follows: Level 1—Quoted prices in active markets for identical assets or liabilities. Level 2—Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly. Level 3—Unobservable inputs based on the Company’s own assumptions. The following table s present the fair value hierarchy for those assets or liabilities measured at fair value on a recurring basis: Fair Value as of June 30, 2019 (In thousands) Level 1 Level 2 Level 3 Total Assets (Liabilities): Interest rate swap agreements $ - $ (628) $ - $ (628) Fair Value as of December 31, 2018 (In thousands) Level 1 Level 2 Level 3 Total Assets (Liabilities): Interest rate swap agreements $ - $ (170) $ - $ (170) The Company uses the market approach technique to value its financial liabilities. The Company’s financial assets and liabilities carried at fair value include derivative instruments used to hedge the Company’s interest rate risks. The fair value of the Company’s interest rate swap agreements was based on LIBOR yield curves at the reporting date.

Revenues

Revenues	6 Months Ended
	Jun. 30, 2019
Revenues Disclosure [Abstract]
Revenues	17. Revenues The following table represents a disaggregation of revenue from contracts with customers . Revenue from continuing operations originating from the following geographic areas for the six months ended June 30, 2019 and 2018 consist of : Three Months Ended June 30, 2019 (in thousands) United States United Kingdom Germany Rest of the world Total Instruments, equipment, software and accessories $ 20,920 $ 2,399 $ 3,271 $ 1,753 $ 28,343 Service, maintenance and warranty contracts 910 236 79 16 1,241 Total revenues $ 21,830 $ 2,635 $ 3,350 $ 1,769 $ 29,584 Three Months Ended June 30, 2018 (in thousands) United States United Kingdom Germany Rest of the world Total Instruments, equipment, software and accessories $ 20,478 $ 4,058 $ 3,316 $ 2,156 $ 30,008 Service, maintenance and warranty contracts 1,204 168 129 13 1,514 Total revenues $ 21,682 $ 4,226 $ 3,445 $ 2,169 $ 31,522 Six Months Ended June 30, 2019 (in thousands) United States United Kingdom Germany Rest of the world Total Instruments, equipment and accessories $ 39,591 $ 5,528 $ 6,184 $ 3,798 $ 55,101 Service, maintenance and warranty contracts 2,053 426 176 30 2,685 Total revenues $ 41,644 $ 5,954 $ 6,360 $ 3,828 $ 57,786 Six Months Ended June 30, 2018 (in thousands) United States United Kingdom Germany Rest of the world Total Instruments, equipment and accessories $ 36,695 $ 7,587 $ 7,006 $ 4,400 $ 55,688 Service, maintenance and warranty contracts 2,030 334 198 31 2,593 Total revenues $ 38,725 $ 7,921 $ 7,204 $ 4,431 $ 58,281 Deferred revenue As of June 30, 2019 and December 31, 2018 , the Company had approximately $ 3.5 million and $ 3.8 million, respectively, in deferred revenue comprised of revenue deferred from service contracts and revenue deferred from advance payments. Changes in defe r r ed revenue from service contracts and advance payments from customers during the six months ended June 30, 2019 and 2018 were as follows: Three Months Ended June 30, 2019 (in thousands) Service Contracts Customer Advances Total Balance at March 31, 2019 $ 1,666 $ 2,049 $ 3,715 Deferral of revenue 281 140 421 Recognition of deferred revenue (344) (250) (594) Effect of foreign currency translation (10) - (10) Balance at June 30, 2019 $ 1,593 $ 1,939 $ 3,532 Three Months Ended June 30, 2018 (in thousands) Service Contracts Customer Advances Total Balance at March 31, 2018 $ 1,793 $ 2,060 $ 3,853 Addition due to business combination (1) - (1) Deferral of revenue 1,090 116 1,206 Recognition of deferred revenue (1,169) (323) (1,492) Effect of foreign currency translation (19) - (19) Balance at June 30, 2018 $ 1,694 $ 1,853 $ 3,547 Six Months Ended June 30, 2019 (in thousands) Service Contracts Customer Advances Total Balance at December 31, 2018 $ 1,659 $ 2,161 $ 3,820 Deferral of revenue 1,126 251 1,377 Recognition of deferred revenue (1,192) (473) (1,665) Effect of foreign currency translation - - - Balance at June 30, 2019 $ 1,593 $ 1,939 $ 3,532 Six Months Ended June 30, 2018 (in thousands) Service Contracts Customer Advances Total Balance at December 31, 2017 $ 505 $ - $ 505 Addition due to business combination 848 2,128 2,976 Deferral of revenue 2,283 244 2,527 Recognition of deferred revenue (1,927) (519) (2,446) Effect of foreign currency translation (15) - (15) Balance at June 30, 2018 $ 1,694 $ 1,853 $ 3,547 Allowance for doubtful accounts Activity in the allowance for doubtful accounts was as follows: Six Months Ended June 30, 2019 2018 (in thousands) Balance, beginning of period $ 332 $ 193 Addition due to business combination - 102 Bad debt expense 368 149 Charge-offs and other recoveries (329) - Effect of foreign currency translation (1) 77 Balance, end of period $ 370 $ 521

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2019
Income Tax [Abstract]
Income Taxes Disclosure [Text Block]	18 . Income Tax Income tax benefit from continuing operations was approximately $0.9 million and $0.4 million for the three months ended June 30, 2019 and 2018, respectively. The effective tax rate on continuing operations was 78 .2 % for the three months ended June 30, 201 9 compared with 19.8 % for the same period in 2018. Income tax from continuing operations was a benefit of approximately $0.3 million and an expense of $0.2 million for the six months ended June 30, 2019 and 2018, respectively. The effective tax rate on c ontinuing operations was 10.6 % for the six months ended June 30, 2019, compared with ( 3.3 %) for the same period in 2018. The difference between the Company’s effective tax rates in 2019 and 2018 compared to the U.S. statutory tax rate of 21 % is primaril y due to the mix of year-to-date and forecasted income or losses in the U.S. and foreign tax jurisdictions, the impact of different tax rates in certain foreign jurisdictions, the impact of the inclusion of foreign income in U.S. taxable income under the G ILTI (Global Intangible Low-Taxed Income) tax rules, limitations on interest expense deductions and, in 2018, certain non-deductible acquisition costs. For the three and six months ended June 30, 2019, no income tax expense or benefit was recorded for d iscontinued operations. For the comparable three-and six-month periods in 2018, income tax benefit recorded for discontinued operations was $10 thousand and $0.9 million.

Basis of Presentation and Sum_2

Basis of Presentation and Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2019
Summary of Significant Accounting Policies [Abstract]
Basis of Presentation Policies [Text Block]	Basis of Presentation The unaudited consolidated financial statements of Harvard Bioscience, Inc. and its wholly-owned subsidiaries (collectively, Harvard Bioscience or the Company) as of June 30, 2019 and for the three and six months ended June 30, 2019 and 2018 have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (SEC). Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles (U.S. GAAP) have been condensed or omitted pursuant to such rules and regulations. The December 31, 2018 consolidated balance sheet was derived from audited financial statements, but does not include all disclosures required by U.S. GAAP. However, the Company believes that the disclosures are adequate to make the information presented not misleading. These unaudited consolidated financial statements should be read in conjunction with the consolidated f inancial statements and the notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2018 , which was filed with the SEC on March 18, 2019. In the opinion of management, all adjustments, which incl ude normal recurring adjustments necessary to present a fair statement of financial position as of June 30, 2019 , results of operations and comprehensive income (loss) for the three and six months ended June 30, 2019 and 2018 and cash flows for the six months ended June 30, 2019 and 2018 , as applicable, have been made. The results of operations for the three months ended June 30, 2019 are not necessarily indicative of the operating results for the full fis cal year or any future periods.
Reclassifications [Policy Text Block]	R eclassifications As disclosed in Note 5, on January 22, 2018, the Company sold substantially all the assets of its operating subsidiary, Denville Scientific, Inc. (Denville). The sale of Denville represented a strategic shift that had a major effect on the Company’s operat ions and financial results. As such and pursuant to Accounting Standards Codification (ASC) 205-20 – Presentation of Financial Statements - Discontinued Operations, the operating results of Denville for the three and six months ended June 30, 2018 have been presented in discontinued operations in the consolidated statements of operations. T hese reclassifications and adjustments had no effect on total amounts within the consolidated balance sheet, consolidated statements of operations and comprehensive i ncome ( loss ) , consolidated statements of cash flows for any of the periods presented.
Leases [Policy Text Block]	Leases The Company accounts for its leases in accordance with ASC 842 Leases . The Company leases office space, manufacturi ng facilities, automobiles and equipment. The Company concludes on whether an arrangement is a lease at inception. This determination as to whether an arrangement contains a lease is based on an assessment as to whether a contract conveys the right to the Company to control the use of identified property, plant or equipment for period of time in exchange for considera tion. Leases with an initial term of 12 months or less are not recorded on the balance sheet. The Company recognizes these lease expenses on a straight line basis over the lease term. As of June 30, 2019 , the Company has assessed its contra cts and concluded that its leases consist of operating leases. Operating leases are included in operating lease right-of-use ( ROU) assets, current portion of operating lease liabilities , and operating lease liabilities in the Company’s consolidated balance sheets. ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recogni zed at commencement date based on the present value of lease payments over the lease term. As most of the Company’s leases do not provide an implicit rate, the Company determines an incremental borrowing rate based on the information available at commencem ent date in determining the present value of lease payments. The incremental borrowing rate represents a significant judgment that is based on an analysis of the Company’s credit rating, country risk, treasury and corporate bond yields, as well as comparis on to the Company’s borrowing rate on its most recent loan. The Company uses the implicit rate when readily determinable. The operating lease ROU asset also includes any lease payments made and excludes lease incentives. Lease expense for lease payments is recognized on a straight-line basis over the lease term. The Company has lease agreements with lease and non-lease components, which are generally accounted for separately. Additionally, for its leases, the Company applies a portfolio approach to effecti vely account for the operating lease ROU assets and liabilities.

Accumulated Other Comprehensi_2

Accumulated Other Comprehensive Income (Tables)	6 Months Ended
	Jun. 30, 2019
Accumulated Other Comprehensive Income [Abstract]
Accumulated Other Comprehensive Income [Table Text Block]	Foreign currency Derivatives translation qualifying as Defined benefit (in thousands) adjustments hedges pension plans Total Balance at December 31, 2018 $ (12,630) $ (170) $ (732) $ (13,532) Other comprehensive income (loss) before reclassifications (191) (494) - (685) Amounts reclassified from AOCI - 36 - 36 Other comprehensive income (loss) (191) (458) - (649) Balance at June 30, 2019 $ (12,821) $ (628) $ (732) $ (14,181)

Acquisitions (Tables)

Acquisitions (Tables)	6 Months Ended
	Jun. 30, 2019
Acquisition Disclosure [Abstract]
Schedule of Business Acquisitions [Table Text Block]	(in thousands) Tangible assets $ 34,010 Liabilities assumed (11,949) Net assets 22,061 Goodwill and intangible assets: Goodwill 21,865 Amortizable intangible assets: Trade name 3,524 Developed technology 25,570 Customer relationships 9,837 In-process research and development 1,387 Total amortizable intangible assets 40,318 Deferred tax liabilities, net (13,120) Total goodwill and intangible assets, net of tax 49,063 Acquisition purchase price $ 71,124 Tangible assets and liabilities assumed, as referenced above, consisted of the following: Cash acquired $ 2,576 Accounts receivable, net 5,069 Inventories 11,512 Other current assets 810 Property, plant and equipment, net 3,574 Deferred income tax assets, net 10,469 Tangible assets $ 34,010 Accounts payable and accrued liabilities $ 6,001 Deferred revenue including customer advances 2,976 Other long term liabilities 2,972 Liabilities assumed $ 11,949
Business Acquisition, Pro Forma Information [Table Text Block]	Six Months Ended June 30, 2018 (in thousands) Pro Forma Revenues $ 61,671 Income (loss) from continuing operations (392)

Discontinued Operations (Tables

Discontinued Operations (Tables)	6 Months Ended
	Jun. 30, 2019
Discontinued Operations [Abstract]
Disposal Groups, Including Discontinued Operations,Income Loss [Table Text Blcok]	Three Months Ended Six Months Ended June 30, June 30, 2018 2018 (in thousands) Revenues $ - $ 893 Cost of revenues - (534) Operating and other expenses - (673) Gain on disposal of discontinued operations 24 1,251 Income from discontinued operations before income taxes 24 937 Income tax benefit (10) (883) Income from discontinued operations $ 34 $ 1,820

Goodwill and Other Intangible_2

Goodwill and Other Intangible Assets (Tables)	6 Months Ended
	Jun. 30, 2019
Goodwill And Other Intangible Assets Disclosure [Abstract]
Schedule of Intangible Assets and Goodwill [Table Text Block]	Weighted Average June 30, 2019 December 31, 2018 Life (a) (in thousands) Amortizable intangible assets: Gross Accumulated Amortization Gross Accumulated Amortization Existing technology $ 41,205 $ (18,004) $ 41,268 $ (16,215) 6.6 Years Trade names 7,809 (3,182) 7,828 (2,861) 7.2 Years Distribution agreements/customer relationships 22,603 (10,147) 22,657 (9,509) 10.2 Years In-process research and development 446 (60) 1,387 (30) 6.4 Years Patents 211 (211) 211 (204) - Years Total amortizable intangible assets 72,274 $ (31,604) 73,351 $ (28,819) Indefinite-lived intangible assets: Goodwill 57,239 57,304 Other indefinite-lived intangible assets 1,230 1,232 Total goodwill and other indefinite-lived intangible assets 58,469 58,536 Total intangible assets, gross $ 130,743 $ 131,887 (a) Weighted average life as of June 30, 2019.
Goodwill Rollforward [Table Text Block]	(in thousands) Balance at December 31, 2018 $ 57,304 Effect of change in currency translation (65) Balance at June 30, 2019 $ 57,239

Inventories (Tables)

Inventories (Tables)	6 Months Ended
	Jun. 30, 2019
Inventories Disclosure [Abstract]
Schedule of Inventory [Table Text Block]	June 30, December 31, 2019 2018 (in thousands) Finished goods $ 6,729 $ 6,936 Work in process 4,101 3,667 Raw materials 14,458 14,484 Total $ 25,288 $ 25,087

Property, Plant and Equipment (

Property, Plant and Equipment (Tables)	6 Months Ended
	Jun. 30, 2019
Property, Plant and Equipment Disclosure [Abstract]
Schedule Of Property Plant And Equipment [Table Text Block]	June 30, December 31, 2019 2018 (in thousands) Land, buildings and leasehold improvements $ 2,527 $ 2,468 Machinery and equipment 9,914 9,678 Computer equipment and software 9,814 9,685 Furniture and fixtures 1,406 1,390 Automobiles 114 115 23,775 23,336 Less: accumulated depreciation (18,416) (17,438) Property, plant and equipment, net $ 5,359 $ 5,898

Warranties (Tables)

Warranties (Tables)	6 Months Ended
	Jun. 30, 2019
Warranties Disclosure [Abstract]
Warranty Rollforward Disclosure [Table Text Block]	Beginning (Payments)\ Ending Balance Credits Additions Balance (in thousands) Year ended December 31, 2018 $ 246 (37) 182 $ 391 Six months ended June 30, 2019 $ 391 (79) 6 $ 318

Employee Benefit Plans (Tables)

Employee Benefit Plans (Tables)	6 Months Ended
	Jun. 30, 2019
Employee Benefit Plans Disclosure [Abstract]
Schedule of Changes in Projected Benefit Obligations [Table Text Block]	Three Months Ended Six Months Ended June 30, June 30, 2019 2018 2019 2018 (in thousands) Components of net periodic benefit cost: Interest cost $ 123 $ 118 $ 255 $ 250 Expected return on plan assets (170) (184) (352) (388) Net amortization loss 71 52 147 110 Net periodic benefit cost (income) $ 24 $ (14) $ 50 $ (28)

Leases (Tables)

Leases (Tables)	6 Months Ended
	Jun. 30, 2019
Leases [Abstract]
Lessee, Operating Lease, Disclosure [Table Text Block]	Three Months Ended Six Months Ended June 30, 2019 June 30, 2019 (in thousands) (in thousands) Operating lease cost $ 515 $ 1,038 Short term lease cost 51 127 Sublease income (103) (205) Total lease cost $ 463 $ 960 Supplemental cash flow information related to the Company's operating leases was as follows Six Months Ended June 30, 2019 (in thousands) Cash paid for amounts included in the measurement of lease liabilities Operating cash flows from operating leases $ 1,367 Right-of-use assets obtained in exchange for lease obligations Operating leases $ - Supplemental balance sheet information related to the Company's operating leases was as follows: June 30, 2019 (in thousands) Operating lease right-of use assets $ 8,846 Current portion, operating lease liabilities $ 2,295 Operating lease liabilities, long term 8,714 Total operating lease liabilities $ 11,009 Weighted average remaining lease term 8.5 years Weighted average discount rate 9.2%
Future minimum lease payments for operating leases [Table Text Block]	Operating Leases (in thousands) 2020 $ 2,295 2021 2,108 2022 1,852 2023 1,804 2024 1,798 Thereafter 6,543 Total lease payments 16,400 Less interest (5,391) Total operating lease liabilities $ 11,009

Capital Stock (Tables)

Capital Stock (Tables)	6 Months Ended
	Jun. 30, 2019
Capital Stock Disclosure [Abstract]
Schedule Of Stock Options And Restricted Stock Units Activity Rollforward [Table Text Block]	Stock Options Restricted Stock Units Market Condition RSU's Weighted Stock Average Restricted Market Options Exercise Stock Units Grant Date Condition RSU's Grant Date Outstanding Price Outstanding Fair Value Outstanding Fair Value Balance at December 31, 2018 1,956,732 $ 4.25 1,233,762 $ 3.36 116,944 $ 4.19 Granted 587,909 3.73 599,977 3.19 75,514 4.16 Exercised (2,500) 3.25 - - - - Expired (2,635) 2.28 - - - - Vested (RSUs) - - (550,200) 3.46 (3,778) 4.19 Cancelled / forfeited (356,649) 4.03 (229,883) 3.48 (124,607) 4.19 Balance at June 30, 2019 2,182,857 $ 4.15 1,053,656 $ 3.19 64,073 $ 4.16
Stock Based Compensation Expense Activity By Function [Table Text Block]	Three Months Ended Six Months Ended June 30, June 30, 2019 2018 2019 2018 (in thousands) Cost of revenues $ 8 $ 15 $ 21 $ 26 Sales and marketing 36 102 29 226 General and administrative 529 576 1,080 1,273 Research and development 42 41 76 71 Discontinued operations - - - 150 Total stock-based compensation $ 615 $ 734 $ 1,206 $ 1,746
Basic and Diluted Shares [Table Text Block]	Three Months Ended Six Months Ended June 30, June 30, 2019 2018 2019 2018 Basic 37,735,717 36,082,258 37,682,539 35,774,334 Effect of assumed conversion of employee and director stock options, restricted stock units and Market Condition RSUs - - - - Diluted 37,735,717 36,082,258 37,682,539 35,774,334
Black-Scholes option pricing model [Member]
Share-Based Compensation Arrangement By Share-Based Payment Award [Line Items]
Table Of Assumptions [Table Text Block]	Three Months Ended Six Months Ended June 30, June 30, 2019 2018 2019 2018 Volatility 47.76 % 42.31 % 45.69 % 42.31 % Risk-free interest rate 1.86 % 2.82 % 2.42 % 2.82 % Expected holding period (in years) 4.70 years 4.95 years 4.73 years 4.95 years Dividend yield - % - % - % - %
Monte-Carlo valuation simulation [Member]
Share-Based Compensation Arrangement By Share-Based Payment Award [Line Items]
Table Of Assumptions [Table Text Block]	Six Months Ended June 30, 2019 2018 Volatility 48.00 % 44.02 % Risk-free interest rate 2.50 % 2.27 % Correlation coefficient 0.27 % 0.07 % Dividend yield - % - %

Long Term Debt (Tables)

Long Term Debt (Tables)	6 Months Ended
	Jun. 30, 2019
Long Term Debt Disclosure [Abstract]
Schedule of Debt [Table Text Block]	June 30, December 31, 2019 2018 (in thousands) Long-term debt: Term loan $ 56,197 $ 62,400 Total unamortized deferred financing costs (1,376) (1,605) Total debt 54,821 60,795 Less: current installments (2,800) (6,383) Current unamortized deferred financing costs 393 401 Long-term debt $ 52,414 $ 54,813

Derivative (Tables)

Derivative (Tables)	6 Months Ended
	Jun. 30, 2019
Derivatives [Abstract]
Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]	June 30, 2019 Notional Amount Fair Value (a) Derivatives designated as hedging instruments under ASC 815 Balance sheet classification (in thousands) Interest rate swaps Other assets (long term liabilities) $ 31,591 $ (628) December 31, 2018 Notional Amount Fair Value (a) Derivatives designated as hedging instruments under ASC 815 Balance sheet classification (in thousands) Interest rate swaps Other assets (long term liabilities) $ 34,090 $ (170) (a) See Note 16 for the fair value measurements related to these financial instruments.
Schedule of Cash Flow Hedges Included in AOCI [Table Text Block]	Derivatives in Hedging Relationships Amount of gain (loss) recognized in OCI on derivative (effective portion) Three months ended Six Months Ended June 30, June 30, 2019 2018 2019 2018 (in thousands) Interest rate swaps $ (298) $ 155 $ (494) $ (99)
Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]	Details about AOCI Components Amount reclassified from AOCI into income (effective portion) Three Months Ended Six Months Ended Location of amount reclassified from AOCI June 30, June 30, 2019 2018 2019 2018 into income (effective portion) (in thousands) Interest rate swaps $ 19 $ 70 $ 36 $ 45 Interest expense

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	6 Months Ended
	Jun. 30, 2019
Fair Value Disclosures [Abstract]
Schedule Of Fair Value Assets And Liabilities Measured On Recurring Basis [Table Text Block]	Fair Value as of June 30, 2019 (In thousands) Level 1 Level 2 Level 3 Total Assets (Liabilities): Interest rate swap agreements $ - $ (628) $ - $ (628) Fair Value as of December 31, 2018 (In thousands) Level 1 Level 2 Level 3 Total Assets (Liabilities): Interest rate swap agreements $ - $ (170) $ - $ (170)

Revenues (Tables)

Revenues (Tables)	6 Months Ended
	Jun. 30, 2019
Revenues Disclosure [Abstract]
Disaggregation of Revenue [Table Text Block]	Three Months Ended June 30, 2019 (in thousands) United States United Kingdom Germany Rest of the world Total Instruments, equipment, software and accessories $ 20,920 $ 2,399 $ 3,271 $ 1,753 $ 28,343 Service, maintenance and warranty contracts 910 236 79 16 1,241 Total revenues $ 21,830 $ 2,635 $ 3,350 $ 1,769 $ 29,584 Three Months Ended June 30, 2018 (in thousands) United States United Kingdom Germany Rest of the world Total Instruments, equipment, software and accessories $ 20,478 $ 4,058 $ 3,316 $ 2,156 $ 30,008 Service, maintenance and warranty contracts 1,204 168 129 13 1,514 Total revenues $ 21,682 $ 4,226 $ 3,445 $ 2,169 $ 31,522 Six Months Ended June 30, 2019 (in thousands) United States United Kingdom Germany Rest of the world Total Instruments, equipment and accessories $ 39,591 $ 5,528 $ 6,184 $ 3,798 $ 55,101 Service, maintenance and warranty contracts 2,053 426 176 30 2,685 Total revenues $ 41,644 $ 5,954 $ 6,360 $ 3,828 $ 57,786 Six Months Ended June 30, 2018 (in thousands) United States United Kingdom Germany Rest of the world Total Instruments, equipment and accessories $ 36,695 $ 7,587 $ 7,006 $ 4,400 $ 55,688 Service, maintenance and warranty contracts 2,030 334 198 31 2,593 Total revenues $ 38,725 $ 7,921 $ 7,204 $ 4,431 $ 58,281
Activity in allowance for doubtful accounts [Table Text Block]	Six Months Ended June 30, 2019 2018 (in thousands) Balance, beginning of period $ 332 $ 193 Addition due to business combination - 102 Bad debt expense 368 149 Charge-offs and other recoveries (329) - Effect of foreign currency translation (1) 77 Balance, end of period $ 370 $ 521
Service Contracts [Member]
Deferred Revenue Arrangement [Line Items]
Deferred Revenue, by Arrangement, Disclosure [Table Text Block]	Three Months Ended June 30, 2019 (in thousands) Service Contracts Customer Advances Total Balance at March 31, 2019 $ 1,666 $ 2,049 $ 3,715 Deferral of revenue 281 140 421 Recognition of deferred revenue (344) (250) (594) Effect of foreign currency translation (10) - (10) Balance at June 30, 2019 $ 1,593 $ 1,939 $ 3,532 Three Months Ended June 30, 2018 (in thousands) Service Contracts Customer Advances Total Balance at March 31, 2018 $ 1,793 $ 2,060 $ 3,853 Addition due to business combination (1) - (1) Deferral of revenue 1,090 116 1,206 Recognition of deferred revenue (1,169) (323) (1,492) Effect of foreign currency translation (19) - (19) Balance at June 30, 2018 $ 1,694 $ 1,853 $ 3,547 Six Months Ended June 30, 2019 (in thousands) Service Contracts Customer Advances Total Balance at December 31, 2018 $ 1,659 $ 2,161 $ 3,820 Deferral of revenue 1,126 251 1,377 Recognition of deferred revenue (1,192) (473) (1,665) Effect of foreign currency translation - - - Balance at June 30, 2019 $ 1,593 $ 1,939 $ 3,532 Six Months Ended June 30, 2018 (in thousands) Service Contracts Customer Advances Total Balance at December 31, 2017 $ 505 $ - $ 505 Addition due to business combination 848 2,128 2,976 Deferral of revenue 2,283 244 2,527 Recognition of deferred revenue (1,927) (519) (2,446) Effect of foreign currency translation (15) - (15) Balance at June 30, 2018 $ 1,694 $ 1,853 $ 3,547

Basis of Presentation and Sum_3

Basis of Presentation and Summary of Significant Accounting Policies (Details) - USD ($) $ in Millions	3 Months Ended
	Jun. 30, 2019	Mar. 31, 2019
Summary of Significant Accounting Policies [Abstract]
Immaterial Error Correction	The immaterial misclassification understated current portion, long term debt and overstated long term debt, less current installments.  This misclassification, in the amount of approximately $4.0 million, related to the classification of the Company’s excess cash flow payment made to its lenders during the quarter ended March 31, 2019 as long term instead of current on its consolidated balance sheet at December 31, 2018.  The misclassification had no impact on total reported debt.
Classification of the Company's excess cash flow payment [Member]
Quantifying Misstatement in Current Year Financial Statements [Line Items]
Miscalculation amount		$ 4

Recently Issued Accounting Pr_2

Recently Issued Accounting Pronouncements (Details) - USD ($) $ in Thousands	Jun. 30, 2019	Jan. 01, 2019	Dec. 31, 2018
Leases [Abstract]
Operating Lease, Right-of-Use Asset	$ 8,846	$ 9,400	$ 0
Operating lease liabilities	$ 11,009	$ 11,700

Accumulated Other Comprehensi_3

Accumulated Other Comprehensive Income (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Accumulated Other Comprehensive Income (Loss) [Line Items]
Opening Balance			$ (13,532)
Other Comprehensive Income (Loss) before Reclassifications			(685)
Amounts reclassified from AOCI			36
Other Comprehensive Income (Loss), Net of Tax, total	$ (474)	$ (2,713)	(649)	$ (1,486)
Closing Balance	(14,181)		(14,181)
Foreign currency translation adjustments
Accumulated Other Comprehensive Income (Loss) [Line Items]
Opening Balance			(12,630)
Other Comprehensive Income (Loss) before Reclassifications			(191)
Amounts reclassified from AOCI			0
Other Comprehensive Income (Loss), Net of Tax, total			(191)
Closing Balance	(12,821)		(12,821)
Derivatives qualifying as hedges
Accumulated Other Comprehensive Income (Loss) [Line Items]
Opening Balance			(170)
Other Comprehensive Income (Loss) before Reclassifications			(494)
Amounts reclassified from AOCI			36
Other Comprehensive Income (Loss), Net of Tax, total			(458)
Closing Balance	(628)		(628)
Defined benefit pension plans
Accumulated Other Comprehensive Income (Loss) [Line Items]
Opening Balance			(732)
Other Comprehensive Income (Loss) before Reclassifications			0
Amounts reclassified from AOCI			0
Other Comprehensive Income (Loss), Net of Tax, total			0
Closing Balance	$ (732)		$ (732)

Acquisitions (Narratives) (Deta

Acquisitions (Narratives) (Details) - USD ($) $ in Millions	Jan. 31, 2018	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019
Business Acquisition [Line Items]
Business Acquisition, Effective Date of Acquisition		Jan. 31, 2018
Acquisition purchase price	$ 71.1
Business Acquisition, Description of Acquired Entity				DSI, a St. Paul, Minnesota-based life science research company, is a recognized leader in physiologic monitoring focused on delivering preclinical products, systems, services and solutions to its customers.
Business Acquisition Direct Acquisition Costs In Income Statement			$ 2.6
The results of operations for DSI:
Revenue of Acquiree since Acquisition Date			18.2
Earnings or Loss of Acquiree since Acquisition Date			1.7
Busniess combination purchase accounting inventory fair value step up amortization			3.7
Preliminary amount of inventory fair value step up			3.8
Intangible asset amortization expense			$ 1.8
Data Sciences International, Inc. (DSI) [Member]
Business Acquisition [Line Items]
Finite-Lived Intangible Assets, Weighted Average Useful Life				9 years 3 months 18 days
Trade Names [Member]
Business Acquisition [Line Items]
Finite-Lived Intangible Assets, Weighted Average Useful Life				7 years 2 months 12 days
Trade Names [Member] | Data Sciences International, Inc. (DSI) [Member]
Business Acquisition [Line Items]
Finite-Lived Intangible Assets, Weighted Average Useful Life				9 years 4 months 24 days
Developed Technology [Member]
Business Acquisition [Line Items]
Finite-Lived Intangible Assets, Weighted Average Useful Life				6 years 7 months 6 days
Developed Technology [Member] | Data Sciences International, Inc. (DSI) [Member]
Business Acquisition [Line Items]
Finite-Lived Intangible Assets, Weighted Average Useful Life				8 years 2 months 12 days
Customer Relationships [Member]
Business Acquisition [Line Items]
Finite-Lived Intangible Assets, Weighted Average Useful Life				10 years 2 months 12 days
Customer Relationships [Member] | Data Sciences International, Inc. (DSI) [Member]
Business Acquisition [Line Items]
Finite-Lived Intangible Assets, Weighted Average Useful Life				12 years 4 months 24 days
In-process research and development [Member]
Business Acquisition [Line Items]
Finite-Lived Intangible Assets, Weighted Average Useful Life				6 years 4 months 24 days
In-process research and development [Member] | Data Sciences International, Inc. (DSI) [Member]
Business Acquisition [Line Items]
Finite-Lived Intangible Assets, Weighted Average Useful Life				7 years 4 months 24 days

Acquisitions (Details)

Acquisitions (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2018	Jun. 30, 2019	Dec. 31, 2018	Jan. 31, 2018
Goodwill and intangible assets
Goodwill		$ 57,239	$ 57,304
Data Sciences International, Inc. (DSI) [Member]
Recognized Identifiable Assets Acquired and Liabilities Assumed [Abstract]
Tangible assets				$ 34,010
Liabilities assumed				(11,949)
Net assets				22,061
Goodwill and intangible assets
Goodwill				21,865
Amortizable intangible assets				40,318
Deferred tax, net				(13,120)
Total goodwill and intangible assets, net of tax				49,063
Acquisition purchase price				71,124
Tangible assets and liabilities assumed, as referenced above, preliminarily consist of the following:
Cash acquired				2,576
Accounts receivable, net				5,069
Inventories				11,512
Other current assets				810
Property, plant and equipment, net				3,574
Deferred income tax assets, net				10,469
Tangible assets				34,010
Accounts payable and accrued liabilities				6,001
Deferred revenue including customer advances				2,976
Other long term liabilities				2,972
Liabilities assumed				11,949
Business Acquisitions Pro Forma Revenue	$ 61,671
Business Acquisitions Pro Forma Net Income Loss	$ (392)
Trade Names [Member] | Data Sciences International, Inc. (DSI) [Member]
Goodwill and intangible assets
Amortizable intangible assets				3,524
Developed Technology [Member] | Data Sciences International, Inc. (DSI) [Member]
Goodwill and intangible assets
Amortizable intangible assets				25,570
Customer Relationships [Member] | Data Sciences International, Inc. (DSI) [Member]
Goodwill and intangible assets
Amortizable intangible assets				9,837
In-process research and development [Member] | Data Sciences International, Inc. (DSI) [Member]
Goodwill and intangible assets
Amortizable intangible assets				$ 1,387

Discontinued Operations (Narrat

Discontinued Operations (Narrative) (Details) - USD ($)	Jan. 22, 2018	Jun. 30, 2019	Jun. 30, 2019	Jun. 30, 2018
Discontinued Operations [Abstract]
Discontinued Operation, Name	Denville
Sale price of of assets Denville	$ 20,000,000
Earn out provision of discontinued operations	3,000,000
Proceeds From Divestiture Of Business			$ 1,020,000	$ 15,754,000
Contingent Consideration, Earn-out	3,000,000
Potential consideration year 2018	2,000,000
Potential consideration year 2019	$ 1,000,000
Earnout earned, year 2018		$ 0
Contingent consideration earnout maximum		$ 1,000,000	1,000,000
Earn out performance metrics period	2 years
Proceeds from divestiture of DSI			$ 1,020,000	$ 15,754,000

Discontinued Operations - incom

Discontinued Operations - income (loss) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Discontinued Operation, Income Statement Disclosures [Abstract]
Revenues		$ 0		$ 893
Cost of revenues		0		(534)
Operating and other expenses		0		(673)
Gain on disposal of discontinued operations		24		1,251
Income (loss) from discontinued operations before income taxes	$ 0	24	$ 0	937
Income tax (benefit) expense	0	(10)	0	(883)
Income (loss) from discontinued operations	$ 0	$ 34	$ 0	$ 1,820

Goodwill and Other Intangible_3

Goodwill and Other Intangible Assets (Narratives) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Goodwill And Other Intangible Assets Disclosure [Abstract]
Amortization of intangible assets	$ 1,436	$ 1,412	$ 2,866	$ 2,515
Impairment charges	941	$ 0	941	$ 0
Remaining year ending December 31, 2019	5,600		5,600
Year ending December 31, 2020	5,600		5,600
Year ending December 31, 2021	5,600		5,600
Year ending December 31, 2022	5,500		5,500
Year ending December 31, 2023	5,400		5,400
Year ending December 31, 2024	$ 5,300		$ 5,300

Goodwill and Other Intangible_4

Goodwill and Other Intangible Assets (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2019	Dec. 31, 2018
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	$ 72,274	$ 73,351
Finite-Lived Intangible Assets, Accumulated Amortization	(31,604)	(28,819)
Goodwill	57,239	57,304
Other indefinite lived intangible assets	1,230	1,232
Total goodwill and other indefinite lived intangible assets	58,469	58,536
Total intangible assets	130,743	131,887
Existing technology [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	41,205	41,268
Finite-Lived Intangible Assets, Accumulated Amortization	$ (18,004)	(16,215)
Finite-Lived Intangible Assets, Weighted Average Useful Life	6 years 7 months 6 days
Trade Names [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	$ 7,809	7,828
Finite-Lived Intangible Assets, Accumulated Amortization	$ (3,182)	(2,861)
Finite-Lived Intangible Assets, Weighted Average Useful Life	7 years 2 months 12 days
Distribution agreements/customer relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	$ 22,603	22,657
Finite-Lived Intangible Assets, Accumulated Amortization	$ (10,147)	(9,509)
Finite-Lived Intangible Assets, Weighted Average Useful Life	10 years 2 months 12 days
In-process research and development [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	$ 446	1,387
Finite-Lived Intangible Assets, Accumulated Amortization	$ (60)	(30)
Finite-Lived Intangible Assets, Weighted Average Useful Life	6 years 4 months 24 days
Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	$ 211	211
Finite-Lived Intangible Assets, Accumulated Amortization	$ (211)	$ (204)

Goodwill and Other Intangible_5

Goodwill and Other Intangible Assets - Change in carrying amount of goodwill (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2019USD ($)
Goodwill And Other Intangible Assets Disclosure [Abstract]
Goodwill, Beginning Balance	$ 57,304
Effect of change in currency translation	(65)
Goodwill, Ending Balance	$ 57,239

Inventories (Details)

Inventories (Details) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Inventories Disclosure [Abstract]
Finished Goods	$ 6,729	$ 6,936
Work in Process	4,101	3,667
Raw Materials	14,458	14,484
Total Inventories, Net	$ 25,288	$ 25,087

Property, Plant and Equipment_2

Property, Plant and Equipment (Details) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	$ 23,775	$ 23,336
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment	(18,416)	(17,438)
Property, plant and equipment, net	5,359	5,898
Land, buildings and leasehold improvements [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	2,527	2,468
Machinery and equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	9,914	9,678
Computer equipment and software [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	9,814	9,685
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	1,406	1,390
Automobiles [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	$ 114	$ 115

Related Party Transactions (Nar

Related Party Transactions (Narratives) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Business Acquisition [Line Items]
Operating Leases, Rent Expense, Net				$ 1,400
MCS GmbH (MCS) and Triangle BioSystems, Inc. [Member]
Business Acquisition [Line Items]
Operating Leases, Rent Expense, Net	$ 89	$ 81	$ 178	$ 171

Warranties (Details)

Warranties (Details) - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2019	Dec. 31, 2018
Product Warranty Disclosure [Abstract]
Warranty, Beginning Balance	$ 391	$ 246
Warranty (payments) or credits	(79)	(37)
Warranty additions	6	182
Warranty, Ending Balance	$ 318	$ 391

Employee Benefit Plans (Narrati

Employee Benefit Plans (Narratives) (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2018
Employee Benefit Plans Disclosure [Abstract]
Expected employer contribution in current remaining fiscal year	$ 0.3		$ 0.3
Defined Benefit Plan Payments In Current Fiscal Year	0.2	$ 0.2	0.4	$ 0.4
Defined Benefit Plans Liabilities Noncurrent	$ 0.9		$ 0.9		$ 0.9

Employee Benefit Plans (Details

Employee Benefit Plans (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Employee Benefit Plans Disclosure [Abstract]
Interest Cost	$ 123	$ 118	$ 255	$ 250
Expected Return on Plan Assets	(170)	(184)	(352)	(388)
Net Amortization Loss	71	52	147	110
Net Periodic Benefit Cost, Total	$ 24	$ (14)	$ 50	$ (28)

Leases (Narratives) (Details)

Leases (Narratives) (Details) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jan. 01, 2019	Dec. 31, 2018
Leases [Abstract]
Lease Expiration Date	Dec. 31, 2023
Operating Lease, Right-of-Use Asset	$ 8,846		$ 9,400	$ 0
Operating lease liabilities	$ 11,009		$ 11,700
Operating Leases, Rent Expense, Net		$ 1,400

Leases - Components of lease ex

Leases - Components of lease expense and other supplementary information (Details) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2019	Jan. 01, 2019	Dec. 31, 2018
Components of lease expense:
Operating lease cost	$ 515	$ 1,038
Short term lease cost	51	127
Sublease income	(103)	(205)
Total lease cost	463	960
Supplemental cash flow information [Abstract]
Operating cash flows from operating leases	1,367
Right-of-use assets obtained in exchange for lease obligations, operating leases	0
Supplemental balance sheet information [Abstract]
Operating lease right-of use assets	8,846	8,846	$ 9,400	$ 0
Current portion, operating lease liabilities	2,295	2,295		0
Operating lease liabilities, long term	8,714	8,714		$ 0
Operating lease liabilities	$ 11,009	$ 11,009	$ 11,700
Weighted average remaining lease term	8 years 6 months	8 years 6 months
Weighted average discount rate	9.20%	9.20%

Leases - Maturity (Details)

Leases - Maturity (Details) - USD ($) $ in Thousands	Jun. 30, 2019	Jan. 01, 2019
Leases [Abstract]
2020	$ 2,295
2021	2,108
2022	1,852
2023	1,804
2024	1,798
Thereafter	6,543
Total lease payments	16,400
Less interest	(5,391)
Total operating lease liabilities	$ 11,009	$ 11,700

Capital Stock (Narratives) (Det

Capital Stock (Narratives) (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended			6 Months Ended
	Jun. 30, 2019	Mar. 31, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2018	Apr. 02, 2018
Common stock
Common Stock- Shares Authorized	80,000,000			80,000,000		80,000,000
Common Stock- Shares Issued	45,639,892			45,639,892		45,124,309
Common Stock- Shares Outstanding	37,894,385			37,894,385		37,378,802
Preferred Stock
Preferred stock issued or outstanding	0			0
Preferred Stock - Shares Authorized	5,000,000			5,000,000		5,000,000
Employee Stock Purchase Plan (as amended, the ESPP)
Total amount of common stock issued under ESOP	984,547			984,547
Employee Stock Purchase Plan Shares Authorized	1,400,000			1,400,000
Share-based Compensation Arrangement by Share-based Payment Award, Discount from Market Price, Offering Date	85.00%
Stock issued during the year, Shares, Employee Stock Purchase Plans	94,000		25,000	93,785,000	24,907
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized							20,908,929
Increase In Number Of Shares Authorized For Issuance Under Stock Option And Incentive Plan							3,400,000
Target number of these restricted stock units				599,977
Deferred Compensation Arrangement with Individual, Maximum Contractual Term	10 years
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount				3,300,586	4,737,057
Weighted Average Estimated Black Scholes Value Of Option Grants	$ 0.97		$ 1.81	$ 1.56	$ 1.81
Stock Issued During Period, Value, Restricted Stock Award, Gross	$ 0		$ 3	$ 0	$ 8
Maximum percentage of target number of restricted stock units	150.00%
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value				$ 3.73
Stock options, Granted				587,909
Market Condition Restricted Stock Unit [Member]
Employee Stock Purchase Plan (as amended, the ESPP)
Target number of these restricted stock units				75,514
2018 Market Condition RSUs [Member]
Employee Stock Purchase Plan (as amended, the ESPP)
Target number of these restricted stock units				7,556
Maximum percentage of target number of restricted stock units				150.00%
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value					$ 4.19
2019 Market Condition RSUs [Member]
Employee Stock Purchase Plan (as amended, the ESPP)
Target number of these restricted stock units				56,517
Maximum percentage of target number of restricted stock units				150.00%
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value		$ 4.16
Minimum [Member]
Employee Stock Purchase Plan (as amended, the ESPP)
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	1 year
Maximum [Member]
Employee Stock Purchase Plan (as amended, the ESPP)
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	4 years

Capital Stock - Stock options a

Capital Stock - Stock options and restricted stock activity (Details) - $ / shares	3 Months Ended	6 Months Ended
	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Share-Based Compensation Arrangement By Share-Based Payment Award [Line Items]
Opening Balance Stock Options Outstanding		1,956,732
Stock options, Granted		587,909
Stock option, Exercised	(421,000)	(3,000)	(719,000)
Expired		(2,635)
Stock options, Cancelled and Forfeited		(356,649)
Closing Balance Stock Options Outstanding		2,182,857
Begining Balance Weighted Average Exercise Price		$ 4.25
Stock Options, Weighted Average Exercise Price, Granted		3.73
Stock Options, Weighted Average Exercise Price, Exercised		3.25
Stock Options, Weighted Average Exercise Price, Expired		2.28
Stock Options, Weighted Average Exercise Price, Cancelled / Forfeited		4.03
Closing Balance Weighted Average Exercise Price		$ 4.15
Begining Balance Restricted Stock Units Outstanding		1,233,762
Restricted stock units, Granted		599,977
Retricted Stock Units, Vested		(550,200)
Restricted Stock Units, Cancelled/ Forfeited		(229,883)
Closing Balance Restricted Stock Units Outstanding		1,053,656
Begining Balance Grant Date Fair Value Of Restricted Stock Units		$ 3.36
Restricted Stock Units Grant Date Fair Value, Granted		3.19
Restricted Stock Unit, Grant Date Fair Value, Vested		3.46
Restricted Stock Unit Grant Date Fair Value, Forfeited		3.48
Closing Balance Grant Date Fair Value Of Restricted Stock Units		$ 3.19
Market Condition Restricted Stock Unit [Member]
Share-Based Compensation Arrangement By Share-Based Payment Award [Line Items]
Begining Balance Restricted Stock Units Outstanding		116,944
Restricted stock units, Granted		75,514
Retricted Stock Units, Vested		(3,778)
Restricted Stock Units, Cancelled/ Forfeited		(124,607)
Closing Balance Restricted Stock Units Outstanding		64,073
Begining Balance Grant Date Fair Value Of Restricted Stock Units		$ 4.19
Restricted Stock Units Grant Date Fair Value, Granted		4.16
Restricted Stock Unit, Grant Date Fair Value, Vested		4.19
Restricted Stock Unit Grant Date Fair Value, Forfeited		4.19
Closing Balance Grant Date Fair Value Of Restricted Stock Units		$ 4.16

Capital Stock - Assumptions Bla

Capital Stock - Assumptions Black Scholes and Monte Carlo (Details)	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Black-Scholes option pricing model [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]
Volatility	47.76%	42.31%	45.69%	42.31%
Risk-free interest rate	1.86%	2.82%	2.42%	2.82%
Expected holding period (in years)	4 years 8 months 12 days	4 years 11 months 12 days	4 years 8 months 23 days	4 years 11 months 12 days
Dividend yield	0.00%	0.00%	0.00%	0.00%
Monte-Carlo valuation simulation [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]
Volatility	0.00%		48.00%	44.02%
Risk-free interest rate	0.00%		2.50%	2.27%
Correlation coefficient	0.00%		0.27%	0.07%
Dividend yield	0.00%		0.00%	0.00%

Capital Stock - Stock-based com

Capital Stock - Stock-based compensation expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based Compensation	$ 615	$ 734	$ 1,206	$ 1,746
Cost of Sales [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based Compensation	8	15	21	26
Selling and Marketing Expense [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based Compensation	36	102	29	226
General and Administrative Expense [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based Compensation	529	576	1,080	1,273
Research and Development Expense [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based Compensation	42	41	76	71
Discontinued Operations [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based Compensation	$ 0	$ 0	$ 0	$ 150

Capital Stock - Weighted averag

Capital Stock - Weighted average number of shares (Details) - shares	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Weighted Average Number Diluted Shares Outstanding Adjustment [Abstract]
Basic	37,735,717	36,082,258	37,682,539	35,774,334
Effect of assumed conversion of employee and director stock options, restricted stock units and Market Condition RSU's	0	0	0	0
Diluted	37,735,717	36,082,258	37,682,539	35,774,334

Long Term Debt (Narratives) (De

Long Term Debt (Narratives) (Details) - USD ($) $ in Thousands	Jan. 31, 2018	Jun. 30, 2019	Mar. 31, 2019	Jun. 30, 2019	Dec. 31, 2018	Jun. 30, 2018	Jan. 22, 2018
Debt Instrument [Line Items]
Secured Debt		$ 54,821		$ 54,821	$ 60,795
Line of Credit Facility, Maximum Borrowing Capacity	$ 25,000
Maturity of debt instrument in years and months				5 years
Debt Instrument, Payment Terms	the outstanding term loans began to amortize in equal quarterly installments equal to $0.4 million per quarter on such date and during each of the next three quarters thereafter, $0.6 million per quarter during the next four quarters thereafter and $0.8 million per quarter thereafter, with a balloon payment at maturity.
Debt Instrument Quarterly Payment Current Year						$ 400
Debt Instrument Quarterly Payment Next Year						600
Debt Instrument Quarterly Payment Thereafter						$ 800
Limitation on pledges of capital stock of foreign subsidiaries		65.00%		65.00%
Line of Credit Facility, Amount Outstanding							$ 11,900
Line of Credit Facility, Remaining Borrowing Capacity		$ 9,500		$ 9,500
Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity	$ 25,000
Line of Credit Facility, Amount Outstanding	$ 4,800
Revolving Credit Facility [Member] | Base Rate [Member]
Debt Instrument [Line Items]
Debt Instrument, Description Of Variable Rate Basis	a base rate plus 4.75%
Basis Spread on Variable Rate	4.75%
Floor Interest Rate	4.25%
Revolving Credit Facility [Member] | London Interbank Offered Rate (LIBOR) [Member]
Debt Instrument [Line Items]
Debt Instrument, Description Of Variable Rate Basis	London Interbank Offered Rate (LIBOR) rate plus 6.25%
Basis Spread on Variable Rate	6.25%
Floor Interest Rate	1.25%
Term Loan [Member]
Debt Instrument [Line Items]
Secured Debt	$ 64,000
Percentage of excess cash flow		50.00%		50.00%
Prepayment of senior debt		$ 1,000
Interest Rate As Of Reporting Date		8.85%		8.85%
Excess cash flow [Member]
Debt Instrument [Line Items]
Prepayment of senior debt			$ 4,000
Denville Transaction [Member]
Debt Instrument [Line Items]
Prepayment of senior debt		$ 1,000

Long Term Debt - Borrowings (De

Long Term Debt - Borrowings (Details) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Debt Instrument
Term Loan	$ 56,197	$ 62,400
Total unamortized deferred financing costs	(1,376)	(1,605)
Total Debt	54,821	60,795
Less: current installments	(2,800)	(6,383)
Current unamortized deferred financing costs	393	401
Long-term debt	$ 52,414	$ 54,813

Derivative (Narratives) (Detail

Derivative (Narratives) (Details) - USD ($)	Jan. 31, 2018	Jun. 30, 2019	Jun. 30, 2019	Dec. 31, 2018
Derivative Instruments And Hedging Activities Disclosure [Line Items]
Deferred losses on derivative instruments accumulated in AOCI expected to be reclassified to earnings		$ 93,000	$ 200,000
Derivative Interest Rate Swap Effective Percentage		100.00%
Secured Debt		$ 54,821,000	54,821,000	$ 60,795,000
Line of Credit Facility, Maximum Borrowing Capacity	$ 25,000,000
Other liabilities-non current [Member] | Derivatives qualifying as hedges [Member]
Derivative Instruments And Hedging Activities Disclosure [Line Items]
Notional Amount of Interest Rate Derivatives		$ 31,591,000	$ 31,591,000	$ 34,090,000
Term Loan [Member]
Derivative Instruments And Hedging Activities Disclosure [Line Items]
Notional Amount of Interest Rate Swaps	$ 36,000,000
LIBOR Fixed Rate	2.72%
Secured Debt	$ 64,000,000

Derivative (Details)

Derivative (Details) - Other liabilities-non current [Member] - Derivatives qualifying as hedges [Member] - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Derivatives, Fair Value [Line Items]
Notional Amount of Interest Rate Derivatives	$ 31,591	$ 34,090
Derivative Liability, Fair Value, Net	$ (628)	$ (170)

Derivative - Other comprehensiv

Derivative - Other comprehensive income loss (Details) - Derivatives qualifying as hedges [Member] - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Derivative Instruments, Gain (Loss) [Line Items]
Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion	$ (298,000)	$ 155,000	$ (494,000)	$ (99,000)
Interest Expense [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion	$ 19,000	$ 70,000	$ 36,000	$ 45,000

Fair Value Measurements (Detail

Fair Value Measurements (Details) - Derivatives qualifying as hedges [Member] - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Derivative Liabilities	$ (628)	$ (170)
Fair Value, Inputs, Level 1 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Derivative Liabilities	0	0
Fair Value, Inputs, Level 2 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Derivative Liabilities	(628)	(170)
Fair Value, Inputs, Level 3 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Derivative Liabilities	$ 0	$ 0

Revenues - Disaggregation (Deta

Revenues - Disaggregation (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Disaggregation of Revenue [Line Items]
Revenues	$ 29,584	$ 31,522	$ 57,786	$ 58,281
Instruments, equipment software and accessories [Member]
Disaggregation of Revenue [Line Items]
Revenues	28,343	30,008	55,101	55,688
Service, maintenance and warranty contracts [Member]
Disaggregation of Revenue [Line Items]
Revenues	1,241	1,514	2,685	2,593
Segment, Geographical, United States [Member]
Disaggregation of Revenue [Line Items]
Revenues	21,830	21,682	41,644	38,725
Segment, Geographical, United States [Member] | Instruments, equipment software and accessories [Member]
Disaggregation of Revenue [Line Items]
Revenues	20,920	20,478	39,591	36,695
Segment, Geographical, United States [Member] | Service, maintenance and warranty contracts [Member]
Disaggregation of Revenue [Line Items]
Revenues	910	1,204	2,053	2,030
Segment, Geographical, United Kingdom [Member]
Disaggregation of Revenue [Line Items]
Revenues	2,635	4,226	5,954	7,921
Segment, Geographical, United Kingdom [Member] | Instruments, equipment software and accessories [Member]
Disaggregation of Revenue [Line Items]
Revenues	2,399	4,058	5,528	7,587
Segment, Geographical, United Kingdom [Member] | Service, maintenance and warranty contracts [Member]
Disaggregation of Revenue [Line Items]
Revenues	236	168	426	334
Segment, Geographical, Germany [Member]
Disaggregation of Revenue [Line Items]
Revenues	3,350	3,445	6,360	7,204
Segment, Geographical, Germany [Member] | Instruments, equipment software and accessories [Member]
Disaggregation of Revenue [Line Items]
Revenues	3,271	3,316	6,184	7,006
Segment, Geographical, Germany [Member] | Service, maintenance and warranty contracts [Member]
Disaggregation of Revenue [Line Items]
Revenues	79	129	176	198
Rest Of The World [Member]
Disaggregation of Revenue [Line Items]
Revenues	1,769	2,169	3,828	4,431
Rest Of The World [Member] | Instruments, equipment software and accessories [Member]
Disaggregation of Revenue [Line Items]
Revenues	1,753	2,156	3,798	4,400
Rest Of The World [Member] | Service, maintenance and warranty contracts [Member]
Disaggregation of Revenue [Line Items]
Revenues	$ 16	$ 13	$ 30	$ 31

Revenues - Deferred revenue (De

Revenues - Deferred revenue (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Movement in Deferred Revenue [Roll Forward]
Deferred Revenue, beginning balance	$ 3,715	$ 3,853	$ 3,820	$ 505
Addition due to business combination		(1)		2,976
Deferral of revenue	421	1,206	1,377	2,527
Recognition of deferred revenue	(594)	(1,492)	(1,665)	(2,446)
Effect of foreign currency translation	(10)	(19)	0	(15)
Deferred Revenue, ending balance	3,532	3,547	3,532	3,547
Service Contracts [Member]
Movement in Deferred Revenue [Roll Forward]
Deferred Revenue, beginning balance	1,666	1,793	1,659	505
Addition due to business combination		(1)		848
Deferral of revenue	281	1,090	1,126	2,283
Recognition of deferred revenue	(344)	(1,169)	(1,192)	(1,927)
Effect of foreign currency translation	(10)	(19)	0	(15)
Deferred Revenue, ending balance	1,593	1,694	1,593	1,694
Customer Advances [Member]
Movement in Deferred Revenue [Roll Forward]
Deferred Revenue, beginning balance	2,049	2,060	2,161	0
Addition due to business combination		0		2,128
Deferral of revenue	140	116	251	244
Recognition of deferred revenue	(250)	(323)	(473)	(519)
Effect of foreign currency translation	0	0	0	0
Deferred Revenue, ending balance	$ 1,939	$ 1,853	$ 1,939	$ 1,853

Revenues - Allowance for doubtf

Revenues - Allowance for doubtful debts (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
AllowanceForDoubtfulAccountsReceivableRollforward
Balance, beginning of period	$ 332	$ 193
Addition due to business combination	0	102
Bad debt expense	368	149
Bad debt (recoveries)	(329)	0
Effect of foreign currency translation adjustment	(1)	77
Balance, end of period	$ 370	$ 521

Income Tax (Narratives) (Detail

Income Tax (Narratives) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Income Tax [Abstract]
Effective Income Tax Rate	78.20%	19.80%	10.60%	(3.30%)
Income tax expense (benefit)	$ (885)	$ (369)	$ (309)	$ 236
Discontinued Operation, Tax Effect of Discontinued Operation	$ 0	$ (10)	$ 0	$ (883)
US Federal Income Tax Rate, based on Tax Cuts And Jobs Act Of 2017			21.00%